

Synthesis of C(2)-Substituted *manno*-Configured Tetrahydroimidazopyridines and Their Evaluation as Inhibitors of Snail β -Mannosidase

by Miroslav Terinek and Andrea Vasella*

Laboratorium für Organische Chemie, ETH-Hönggerberg, Wolfgang Pauli-Strasse 10, CH-8093 Zürich


It was shown that retaining β -glucosidases and galactosidases of families 1–3 feature a strong interaction between C(2)OH of the substrate and the catalytic nucleophile. An analogous interaction can hardly take place for retaining β -mannosidases. A structure–activity comparison between the inhibition of the β -glucosidase from *Caldocellum saccharolyticum* (family 1) and β -glucosidase from sweet almonds by the *gluco*-imidazoles **1–6**, and the inhibition of snail β -mannosidase by the corresponding *manno*-imidazoles **8–13** does not show any significant difference, suggesting that also the mechanisms of action of these glycosidases do not differ significantly. For this comparison, we synthesized and tested the *manno*-imidazoles **9–13**, **28**, **29**, **32**, **35**, **40**, **41**, **43**, **46**, **47**, and **50**. Among these, the alkene **29** is the strongest known inhibitor of snail β -mannosidase ($K_i = 6$ nM, non-competitive); the aniline **35** is the strongest competitive inhibitor ($K_i = 8$ nM).

Introduction. – The strong inhibition of β -glucosidases by imidazoles of type **1** [1–3] has been rationalized by the similarity of shape of the inhibitor and of the putative reactive intermediate, an oxycarbenium cation, and by the cooperative interaction of the imidazole with the catalytic nucleophile and acid [4]. A correlation between the inhibition constant and the p*K* value of the C(2)- and C(3)-acetamido imidazoles **7** and **14–16**, and by related azoles has established that substituents at C(3) lower the inhibitory activity [5]. The structure–activity relation (SAR) resulting from varying the C(2)-substituents has been studied in detail [6]. It was shown that the HOCH₂ group at C(2) in **2**, and particularly the flexible hydrophobic PhCH₂CH₂ group in **3** lead to an improved inhibition, with K_i values as low as 0.1 nM (against *Caldocellum saccharolyticum* β -glucosidase)¹. The C(2)-substituents affect both the strength and the type of the inhibition (competitive or mixed, with α varying between 2.5 and 15).

Legler and *Withers* evidenced that the C(2)OH group of β -glucosides and β -galactosides interacts with the catalytic nucleophile of the retaining β -glucosidases and β -galactosidases of families 1 [8], 2 [9], and 3 [10][11]. 2-Deoxy- and 2-deoxy-2-fluoro- β -D-glucosides and -galactosides are cleaved much less readily than the parent substrates, the rate-determining step being deglycosylation of the enzyme. The transition state for this reaction is considered very similar to that of the enzyme glycosylation [9], and the most important interaction in the transition state was considered with the C(2)OH². That 2-deoxyglucosides are cleaved less readily than the parent substrates is surprising, as the OH group at C(2) is known to destabilize an

¹) Similar effects of these substituents on the inhibition of *Escherichia coli* β -galactosidase and almonds β -glucosidase have recently been reported for L-arabinose-derived imidazoles [7].

²) However, a crystal structure of the retaining β -glucosidase from maize (ZMGl1) in complex with 4-nitrophenyl- β -D-thioglucoside showed only interactions of C(3)-, C(4)- and C(6)OH of the glucoside with the enzyme [12].



a) *N*-Iodosuccinimide (NIS), DMF, 80°; 80% of **18**. b) NIS, DMF, 50°; 56% of **19**, 23% of **18**. c) EtMgBr, THF; 88%. d) BCl₃, CH₂Cl₂, -78° → 10°; 97% of **9**, 64% of **13**, 56% of **21**, 85% of **28**. e) 1. EtMgBr, THF, 2. DMF, -35° → 23°; 85%. f) NaBH₄, EtOH; 89%. g) Methyl acrylate, Pd(OAc)₂[P(2-tolyl)₃]₂, K₂CO₃, DMF, 90°; 94% of **24**. h) Styrene, Pd(OAc)₂[P(2-tolyl)₃]₂, K₂CO₃, DMF, 80°; 45% of **25**. i) H₂, Pd/C, AcOEt/MeOH/AcOH; 88% of **11**. j) H₂, Pd(OH)₂/C, AcOEt/MeOH/H₂O/AcOH; 46% of **10**. k) H₂, Pd/C, AcOEt/MeOH/AcOH; 48%. l) 1M aq. HCl, 60°; 85%. m) Phenylacetylene, [Pd(PPh₃)₄], CuI, Et₃N, DMF, 80°; 83%. n) H₂, Pd(OH)₂/C, AcOEt/MeOH/H₂O/AcOH; 80%. o) Diethyl benzylphosphonate, *t*-BuOK, THF, 0°; 87%. p) *N,N*-Dimethylaniline, AlCl₃; 42%.

yielded 88% of the 2-iodo derivative **20**. The unprotected iodoimidazopyridines **21**⁴⁾ and **13** were obtained by BCl₃-promoted debenzylation [16] of **19** (56%) and **20** (64%), respectively.

The 2-(hydroxymethyl)imidazopyridine **9** was synthesized similarly to the *gluco*-analogue **2** [6] by sequential formylation of **20** to the carbaldehyde **22** (85%), reduction of **22** to the alcohol **23** (89%), and debenzylation (BCl₃, 97%).

4) Similarly to the *C*(3)-substituted *gluco*- and *manno*-imidazopyridines **15** and **16** [5], **21** possesses a distorted conformation (see below) and proved a poor inhibitor of the snail β-mannosidase (*K*_i = 73 μM).

To prepare the [2-(methoxycarbonyl)ethyl]-, the 2-(carboxyethyl)-, and the (2-phenylethyl)imidazopyridines **11**, **12**, and **10**, respectively, we again followed the synthesis of their *gluco*-analogues **4**, **5**, and **3** [6]. The reaction of **20** with methyl acrylate or styrene under standard *Heck* conditions ($\text{Pd}(\text{OAc})_2$, Ph_3P , Et_3N or K_2CO_3 , DMF, 80–90°) gave the coupling products **24** (54%) and **25** (25%), respectively, besides variable amounts of **17** and **20**. The yield of **24** and **25** was increased to 94 and 45%, respectively, by replacing $\text{Pd}(\text{OAc})_2/\text{PPh}_3$ by *Herrmann's* catalyst [17]. In contrast to the *gluco*-series [6], addition of H_2O (14% (v/v)) lowered the yield of **25** to 18–24%. Treating the benzylated acrylate **24** with H_2 in the presence of Pd/C (AcOH, 6 bar) afforded the unprotected methyl propanoate **11** (88%) that was hydrolyzed to the acid **12**. Hydrogenation of the 2-phenylethenyl derivative **25** under conditions that led to smooth debenylation of **24** proceeded slowly and yielded mostly the benzylated 2-phenylethyl derivative **26**, while treatment with H_2 in the presence of $\text{Pd}(\text{OH})_2/\text{C}$ gave the desired debenzylated **10** (46%). The overall yield of **10** from the iodoimidazopyridine **20** was significantly increased by proceeding *via* the alkyne **27**. It was obtained in 83% yield by *Sonogashira* coupling [18–20] of **20** with phenylacetylene, followed by hydrogenation (proceeding more rapidly than the one of **25**) to the imidazopyridine **10** (80%).


In addition to the *manno*-imidazopyridines **9**–**13** corresponding to known *gluco*-isomers, we prepared the unprotected phenylethynyl and phenylethenyl derivatives **28** and **29**, respectively, to learn about the influence of flexibility of the substituent at C(2). BCl_3 -Promoted debenylation of **27** yielded 85% of **28**, while the analogous debenylation of **25** to **29** proceeded in only 34%. This yield was increased to 42% by using $\text{AlCl}_3/N,N$ -dimethylaniline [21], providing **29** in an overall yield of 19% from **20**. The overall yield of **29** was increased to 31% by alkenylating **22** with diethyl benzylphosphonate [22][23], to provide 87% of **25**⁵.

Further analogues of the 2-phenylethyl derivative **10**, which were considered of interest, are the phoxymethyl and anilinomethyl derivatives **32** and **35**, respectively (*Scheme 2*). We had observed [6] that the introduction of the HOCH_2 substituent of **2** led to a fourfold increase of the inhibition of the *C. saccharolyticum* β -glucosidase, while the introduction of the H_2NCH_2 group lowered the inhibition from $K_i = 20$ nM to $IC_{50} = 150$ nM. This was rationalized by postulating a binding interaction between the catalytic acid, and both the imidazole N(1) and the $\text{HOCH}_2\text{-C}(2)$ group, and by the competing interaction of the $\text{H}_3\text{N}^+\text{CH-C}(2)$ group and the catalytic acid with N(1). A combination of the hydrophobic Ph group with the H-bond accepting ether O-atom in **32**, or with the (weakly basic) NH in **35** should then lead to strong inhibition.

To prepare the phoxymethyl derivative **32**, we treated the alcohol **23** with SOCl_2 . The chloride **30** was obtained in 86% yield after chromatographic purification. Treating this chloride with phenol and *t*-BuOK in DMF [25] yielded 74% of **31**; other conditions [26–29] (*cf. Exper. Part*) resulted in lower yields. The overall yield of **31** from **23** was increased from 64 to 70% when **30** was not purified. Debenzylation of **31** ($\text{Pd}(\text{OH})_2/\text{C}$, 1 atm.) yielded the [(phenoxy)methyl]imidazopyridine **32** (63%) and the cyclohexyloxymethyl analogue **33** (9%)⁶.

⁵) No reaction was observed when the aldehyde **22** was subjected to a Zn-promoted olefination with α,α -dichlorotoluene in the presence of Me_3SiCl [24].

Scheme 2



a) $\text{SOCl}_2, \text{CH}_2\text{Cl}_2$; 86%. b) $\text{PhOH}, t\text{-BuOK}, \text{DMF}, 80^\circ$; 74%. c) $\text{H}_2, \text{Pd}(\text{OH})_2/\text{C}, \text{AcOEt}/\text{MeOH}/\text{H}_2\text{O}/\text{AcOH}$; 63% of **32** and 9% of **33**. d) 1. Aniline, $\text{MgSO}_4, \text{CH}_2\text{Cl}_2$, 2. $\text{NaBH}_4, \text{EtOH}$; 75%. e) $\text{BCl}_3, \text{CH}_2\text{Cl}_2, -78^\circ \rightarrow 15^\circ$; 77%. f) 1-Fluoro-2-nitrobenzene, $\text{NaH}, \text{DMF}, 80^\circ$; 94%. g) 1-Fluoro-4-nitrobenzene, $\text{NaH}, \text{DMF}, 80^\circ$; 89%. h) 1-Fluoro-2,4-dinitrobenzene, $\text{NaH}, \text{DMF}, 80^\circ$; 63%. i) 1-Fluoro-3-nitrobenzene, $\text{NaH}, \text{DMF}, 140^\circ$; 56%. j) Anisole, $\text{AlCl}_3, \text{CH}_2\text{Cl}_2$; 75% of **40**, 72% of **41**, 75% of **42**, 54% of **43**.


To study the influence of substituents of the Ph ring of **32**, we prepared the mono- and dinitrophenyl-substituted imidazoles **40–43**. For this, the alcohol **23** was *O*-arylated with either 1-fluoro-2-nitro- and 1-fluoro-4-nitrobenzene (NaH , $\text{DMF}, 80^\circ$) to give the imidazopyridines **36** (94%) and **37** (89%), respectively. Similarly, treatment of **23** with NaH and 1-fluoro-3-nitrobenzene at elevated temperature (140°) gave the (3-nitrophenyloxy)methyl derivative **39** (56%). The reaction of **23** with 1-fluoro-2,4-dinitrobenzene (DNP; $\text{NaH}, \text{DMF}, 80^\circ$) did not lead to the (2,4-dinitrophenyloxy)-methyl derivative **38**, which was, however, obtained in 63% yield by performing the reaction at 23° . The imidazopyridines **36–39** were debenzylated with AlCl_3 in the presence of anisole [21] to provide **40** (75%), **41** (72%), **42** (75%), and **43** (54%)⁷. The compound **42** was not stable enough to be tested.

Reductive amination of the carbaldehyde **22** with aniline yielded 75% of the (phenylamino)methyl derivative **34**. Debonylation with BCl_3 provided **35** (77%).

⁶) For examples of a Pd-catalyzed hydrogenation of phenols, cf. [30–34].

⁷) The 4-nitrophenyl ether **41** was also obtained (70%) by BCl_3 -promoted debonylation. Cleavage of the $\text{C}(2)\text{CH}_2\text{--OC}_6\text{H}_4\text{NO}_2$ bond was not observed, while the BCl_3 -promoted debonylation of **31** to **32** was accompanied by substantial cleavage of the $\text{C}(2)\text{CH}_2\text{--OPh}$ bond (cf. *Exper. Part*).

Considering the strong effects of the short HOCH₂ and H₂NCH₂ substituents, we also prepared the ester **46**, the corresponding acid **47**, and the tetrazolylimidazopyridine **50** (Scheme 3). The tetrazolyl group is an established mimic of the carboxy group [35][36]. The acid **47** and the tetrazolyl derivative **50** should, however, differ by their pK values.



a) MnO₂, NaCN, AcOH/MeOH; 78% of **44** or 65% of **44** and 21% of **45** (cf. *Exper. Part*). b) 1. BuLi, THF, 2. ClCOOMe, -78° → 23°; 43%. c) H₂, Pd/C, AcOEt/MeOH/AcOH; 88%. d) KOH, EtOH/H₂O, 50°; 83%. e) 1. EtMgBr, THF, 2. TsCN; 73%. f) Me₃Al, Me₃SiN₃, toluene, 80°; 76%. g) BCl₃, CH₂Cl₂, -78° → 10°; 85% of **50**.

The methyl ester **44** was obtained by two routes. Oxidation of the carbaldehyde **22** (MnO₂, NaCN, MeOH) [37][38] provided **44** in a yield of 78%⁸⁾. A shorter, but lower-yielding route, *viz.* lithiation of the iodoimidazopyridine **20** followed by methoxycarbonylation [40][41] also provided **44** (35–48%), besides the deiodination product **17** (42–58%). Debenzylation of **44** (H₂, Pd/C, AcOH) yielded 88% of the ester **46** that was saponified to afford 83% of the desired acid **47**. The ester **46** was hydrolysed by treatment with 1M HCl at 50–90°.

To synthesize the tetrazolyl derivative **50**, we prepared the 2-carbonitrile **48**, similarly as described for its *gluco*-analogue [6], by treatment of the organomagnesium derivative of the 2-iodoimidazopyridine **20** with TsCN. Attempts to improve the yield of **48** (73%) by Pd-catalyzed coupling of **20** with various metal cyanides were not successful. Thus, treatment of **20** with Zn(CN)₂ in DMF at 150° in the presence of [Pd(PPh₃)₄] [42–44] afforded **48** in only 40% yield, while almost no reaction was observed when **20** was heated with either NaCN, CuI, and [Pd(PPh₃)₄] in DMF or MeCN [45], or with Zn(CN)₂ in DMF in the presence of Pd(OAc)₂ [46]. To form the tetrazole ring, the 2-carbonitrile **48** was subjected to a 1,3-dipolar cycloaddition with *in situ* prepared Al(N₃)₃ [47]. This yielded 76% of the tetrazolyl derivative **49**⁹⁾, which was debenzylated (BCl₃) to afford the tetrazolylimidazopyridine **50** (85%).

⁸⁾ The methyl ester **44** was isolated by aqueous workup, followed by chromatography. If aqueous workup was omitted, chromatography (SiO₂; hexane/AcOEt) led to isolation of **44** (65%) and the corresponding ethyl ester **45** (21%); transesterification was presumably catalysed by residual AcOH (cf. [39]).

⁹⁾ Similar results were obtained when **48** was treated with Me₃SiN₃ in toluene at 110° in the presence of Bu₂SnO [48], while no reaction was observed upon treating **48** with either NaN₃ and NH₄Cl in DMF [49–51], or with NaN₃ in DMSO [52].

The structure of the diiodoimidazopyridine **18** was established by X-ray analysis¹⁰⁾ (*Fig.*). Similarly to its *gluco*-analogue [6], it adopts a conformation between 6H_7 ¹¹⁾ and a sofa conformation with C(7) below the ring plane, as expected from the 1,5-interaction between the I-substituent at C(3) and the C(5)–CH₂OBn group (*cf.* [5][6]). This conformation is also observed in solution, as evidenced by the vicinal coupling constants (*cf.* Table 4 in *Exper. Part*). As expected, a similar conformation is also adopted by the 3-iodoimidazopyridine **19**, while the 2-iodoimidazopyridine **20**, similarly to the parent **17** [2], is a 2 : 1 mixture of the 7H_6 and 6H_7 conformers.




Figure. ORTEP Representation of the crystal structure of the diiodoimidazole **18**

With the exception of the additional signals of the substituents at C(2) and their influence on the chemical shifts of H–C(3), C(2), and C(3), the ¹H- and ¹³C-NMR spectra of the protected and unprotected C(2)-functionalized imidazopyridines **9–12**, **22–48**, and **50** closely resemble those of the 2,3-unsubstituted imidazopyridines **17** and **8** [2]. The ¹³C signals of C(5)–C(8) of the protected imidazoles **27**, **31**, and **34** (*cf.* Table 5 in *Exper. Part*) were assigned on the basis of HSQC.GRASP spectra; those of the other imidazopyridines were assigned by analogy. The signals of C(5)–C(8) of the unprotected imidazopyridines (*cf.* Table 6 in *Exper. Part*) differ from those of the *O*-Bn-

¹⁰⁾ The crystallographic data have been deposited with the *Cambridge Crystallographic Data Centre* as deposition No. CCDC-213714. Copies of the data can be obtained, free of charge, on application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: +44(1223)336033; e-mail: deposit@ccdc.cam.ac.uk).

¹¹⁾ Since the direction of the atom numbering of imidazopyridines (*cf.* **17** in *Scheme 1*) is opposite to that of pyranosides, the sides above and below the plane of the imidazopyridines, as defined by the clockwise and counterclockwise numbering, are interchanged with those defined according to carbohydrate numbering.

protected analogues by upfield shifts of *ca.* 5–9 ppm. A strong deshielding effect for H–C(5), H–C(7), and H–C(8) with $\Delta\delta$ values of 0.14, 0.20, and 0.64 ppm (as compared to **17**), respectively, is observed for the tetrazolyl derivative **49** (*cf.* Table 7 in *Exper. Part*), while the coupling constants did not change significantly.

Enzymatic Tests and Discussion. – The C(2)-substituted imidazopyridines **9–13**, **28**, **29**, **32**, **35**, **40**, **41**, **43**, **46**, **47**, and **50**, and the 2,3-unsubstituted imidazopyridine **8** were tested as inhibitors of β -mannosidase from snail (acetate buffer, 25°, pH 4.5) and α -mannosidase from *Jack* beans (acetate buffer + ZnCl₂, 37°, pH 4.5), with the corresponding 4-nitrophenyl mannosides as substrates. The inhibition data for the β -mannosidase – K_i (in some cases IC_{50}) and K_i/K_M – and the p*K* values for those *manno*- and *gluco*-imidazopyridines that possess the same substituents at C(2) are compiled in Table 1, while the data for the inhibition of this β -mannosidase by the other *manno*-imidazopyridines are listed in Table 2. Table 3 shows the inhibition data for the α -mannosidase from *Jack* beans, and the selectivity of the inhibition of the two mannosidases.

A comparison of the inhibition data in Table 1 shows qualitatively the same dependence of the K_i and K_i/K_M values on the nature of the substituent at C(2) in the *gluco*- and *manno*-series. The difference between the inhibition of the two glucosidases is somewhat smaller than the difference between the inhibition of the glucosidases and the mannosidase. That the *manno*-imidazopyridines, overall, are weaker inhibitors than the *gluco*-imidazopyridines may reflect the different pH optima of the glycosidases, and the different extent to which the imidazopyridines are protonated at the pH of the assay. Considering this, the quantitative differences between the relative K_i values for imidazopyridines of the *gluco*- and *manno*-series are small. This may reflect, in part, the strong interaction of a protonated imidazopyridine with the catalytic nucleophile [4], meaning that only the interaction with the catalytic acid is impaired for the more strongly basic imidazopyridines. This comparison of the SAR in the *gluco*- and *manno*-series evidences that the mechanisms of action for β -glucosidases of family 1 and snail β -mannosidase do not differ significantly. A recent rationalization of the interaction of the catalytic nucleophile with HO–C(2) in β -glucosidases, but not in β -mannosidases [54], suggests that this factor should decrease rather than increase the mechanistic differences. It is, however, not clear how far this finding can be generalised to include retaining β -glucosidases and -mannosidases of other families.


A comparison of the inhibition by the 2-phenylethyl derivative **10** and its analogues **32**, **35**, **40**, **41**, and **43** shows that the aniline **35** is the best inhibitor, in keeping with the rationalization of the effect of the C(2)CH₂OH and C(2)CH₂NH₂ substituents in the *gluco*-imidazopyridines. The phenoxy derivative **32** is only a slightly weaker (mixed-type) inhibitor, and the introduction of a NO₂ group weakens the inhibition, with the exception of the 3-nitro derivative **43**, where the effects of lowering the basic properties of the phenoxy group and of the modified interaction with the β -mannosidase appear to cancel out. Unexpectedly, the restriction of the flexibility of the 2-phenylethyl-imidazopyridine, and the concomitant lowering of the p*K* value, as realized in the phenylethynyl and 2-phenylethenyl derivatives **28** and **29**, respectively, resulted in very strong, albeit no longer competitive inhibition. The carboxylic acid **47** (essentially dissociated at the pH of the assay) is a weak, mixed-type inhibitor ($K_i = 1.21 \mu\text{M}$). The

Table 1. The C(2)-Substituted manno- and gluco-Imidazoles **8–13** and **1–6**: pK_{HA} Values and a Comparison of the Inhibition of the β -Mannosidase from Snail, and of the β -Glucosidases from *Caldocellum saccharolyticum* and from Sweet Almonds

R	No.	pK_{HA}	manno-Imidazoles		gluco-Imidazoles ^{b)}		Inhibition of β -glucosidases ^{b)}				Comparison of K_i values		
			Inhibition of β -mannosidase ^{a)}				from <i>Caldocellum saccharolyticum</i>		from sweet almonds		K_i (rel) β -Mannosidase (snail)	K_i (rel) β -Glucosidase (<i>C. saccharolyticum</i>)	K_i (rel) β -Glucosidase (almonds)
			K_i [nM]	K_i/K_M ^{c)}	No.	pK_{HA}	K_i [nM]	K_i/K_M ^{d)}	K_i [nM]	K_i/K_M ^{e)}			
	13	^{f)}	227	$3.72 \cdot 10^{-4}$	6	4.62	170	$3.33 \cdot 10^{-4}$	640 ^{g)}	$2.13 \cdot 10^{-4}$	1.974	8.50	6.40
H	8	5.7 ^{h)}	115 ⁱ⁾	$1.89 \cdot 10^{-4}$	1	6.12	20 ^{j)}	$3.92 \cdot 10^{-5}$	100	$3.33 \cdot 10^{-5}$	$\equiv 1$	$\equiv 1$	$\equiv 1$
CH ₂ CH ₂ COOH	12	4.15 ^{k)}	100 ^{l)}	$1.64 \cdot 10^{-4}$	5	4.06/7.05	9 ^{g)}	$1.76 \cdot 10^{-5}$	27.5 ^{g)}	$9.17 \cdot 10^{-6}$	0.870	0.45	0.275
CH ₂ OH	9	5.08	67	$1.10 \cdot 10^{-4}$	2	5.22	5	$9.80 \cdot 10^{-6}$	11	$3.67 \cdot 10^{-6}$	0.583	0.25	0.11
CH ₂ CH ₂ COOMe	11	5.52	28	$4.59 \cdot 10^{-5}$	4	6.17	1.8 ^{m)}	$3.53 \cdot 10^{-6}$	9.9 ⁿ⁾	$3.30 \cdot 10^{-6}$	0.243	0.09	0.099
CH ₂ CH ₂ Ph	10	6.04	20	$3.28 \cdot 10^{-5}$	3	6.03	0.11 ^{o)}	$2.16 \cdot 10^{-7}$	1.2	$4.00 \cdot 10^{-7}$	0.174	0.0055	0.012


^{a)} At 25° and pH 4.5. ^{b)} Data taken from [6]. ^{c)} $K_M = 0.61$ mM (mean value of all measurements; cf. *Exper. Part*). ^{d)} $K_M = 0.51$ mM [53]. ^{e)} $K_M = 3.0$ mM. ^{f)} No inflection of the titration curve was observed between pH values of 1.7 and 4.9. ^{g)} $IC_{50}/2$. ^{h)} Taken from [5]. ⁱ⁾ $IC_{50} = 115$ nM [3]. ^{j)} Mixed-type inhibition ($\alpha = 3.2$). ^{k)} No second pK value was observed between pH 2.2 and 5.5. ^{l)} Mixed-type inhibition ($\alpha = 5.3$). ^{m)} Mixed-type inhibition ($\alpha = 2.5$). ⁿ⁾ Non-competitive inhibition. ^{o)} Mixed-type inhibition ($\alpha = 15$).

Table 2. The C(2)-Substituted manno-Imidazoles **8**, **28**, **29**, **32**, **35**, **40**, **41**, **43**, **46**, **47**, and **50**: pK_{HA} Values and a Comparison of the Inhibition of the β -Mannosidase from Snail: K_i , K_i/K_M , and K_i (rel)

 R	manno-Imidazoles		Inhibition of β -mannosidase ^{a)}		
	No.	pK_{HA}	K_i [nM]	K_i/K_M ^{b)}	K_i (rel)
COOH	47	4.70/2.2–5.3 ^{c)}	1210 ($\alpha=4.8$)	$1.98 \cdot 10^{-3}$	10.522
COOMe	46	2.2–5.3 ^{d)}	142 ($\alpha=4.3$)	$2.33 \cdot 10^{-4}$	1.235
CHN ₄	50	4.54/6.41	120 ($\alpha=6.1$)	$1.97 \cdot 10^{-4}$	1.043
H	8	5.7 ^{e)}	115 ^{f)}	$1.89 \cdot 10^{-4}$	$\equiv 1$
CH ₂ OC ₆ H ₄ (2-NO ₂)	40	4.25	43	$7.05 \cdot 10^{-5}$	0.374
CH ₂ OC ₆ H ₄ (4-NO ₂)	41	4.15	22 ($\alpha=3.8$)	$3.61 \cdot 10^{-5}$	0.191
CH ₂ OC ₆ H ₄ (3-NO ₂)	43	4.36	12	$1.97 \cdot 10^{-5}$	0.104
CH ₂ OPh	32	4.39	12 ($\alpha=2.0$)	$1.97 \cdot 10^{-5}$	0.104
CH ₂ NHPh	35	5.09/2.3–7.4 ^{c)}	8	$1.31 \cdot 10^{-5}$	0.070
C \equiv CPh	28	2.1–5.4 ^{d)}	7 ($\alpha=1.8$)	$1.15 \cdot 10^{-5}$	0.061
CH=CHPh	29	4.77	6 ^{g)}	$9.84 \cdot 10^{-6}$	0.052

^{a)} At 25° and pH 4.5. ^{b)} $K_M = 0.61$ mM (mean value of all measurements; cf. *Exper. Part*). ^{c)} No second pK value was observed in the indicated pH range. ^{d)} No inflection of the titration curve was observed between indicated pH values. ^{e)} Taken from [5]. ^{f)} $IC_{50} = 115$ nM [3]. ^{g)} Non-competitive inhibition.

Table 3. The C(2)-Substituted Imidazoles **8**–**13**, **28**, **29**, **32**, **35**, **40**, **41**, **43**, **46**, **47**, and **50**: pK_{HA} Values and a Comparison of the Inhibition of the α -Mannosidase from Jack Beans and of the β -Mannosidase from Snail: K_i , K_i/K_M , and K_i (rel)

 R	manno- Imidazoles	Inhibition of α -mannosidase ^{a)}		Inhibition of β -mannosidase ^{b)}	Comparison of K_i values		
		No.	pK_{HA}	K_i [μ M]	K_i/K_M ^{c)}	K_i [nM]	K_i (rel) α -mannosidase (Jack beans)
COOMe	46	2.2–5.3 ^{d)}	12.5	$5.43 \cdot 10^{-3}$	142	16.667	88.0
CH ₂ OH	9	5.08	3.78	$1.64 \cdot 10^{-3}$	67	5.04	56.4
I	13	1.7–4.9 ^{d)}	3.50	$1.52 \cdot 10^{-3}$	227	4.667	15.4
C \equiv CPh	28	2.1–5.4 ^{d)}	2.41	$1.05 \cdot 10^{-3}$	7	3.213	344.3
COOH	47	4.70/2.2–5.3 ^{e)}	1.33	$5.78 \cdot 10^{-4}$	1210	1.773	1.1
CHN ₄	50	4.54/6.41	0.78	$3.39 \cdot 10^{-4}$	120	1.04	6.5
CH ₂ CH ₂ COOH	12	4.15/2.2–5.5 ^{e)}	0.78	$3.39 \cdot 10^{-4}$	100	1.04	7.8
H	8	5.7 ^{f)}	0.75 ^{g)}	$3.26 \cdot 10^{-4}$	115	$\equiv 1$	6.5
CH ₂ CH ₂ COOMe	11	5.52	0.60	$2.61 \cdot 10^{-4}$	28	0.8	21.4
CH ₂ OPh	32	4.39	0.273	$1.19 \cdot 10^{-4}$	12	0.364	22.8
CH ₂ CH ₂ Ph	10	6.04	0.23	$1.00 \cdot 10^{-4}$	20	0.307	11.5
CH=CHPh	29	4.77	0.15	$6.52 \cdot 10^{-5}$	6	0.2	25
CH ₂ OC ₆ H ₄ (3-NO ₂)	43	4.36	0.125	$5.43 \cdot 10^{-5}$	12	0.167	10.4
CH ₂ OC ₆ H ₄ (2-NO ₂)	40	4.25	0.094	$4.09 \cdot 10^{-5}$	43	0.125	2.2
CH ₂ NHPh	35	5.09/2.3–7.4 ^{e)}	0.068	$2.96 \cdot 10^{-5}$	8	0.091	8.5
CH ₂ OC ₆ H ₄ (4-NO ₂)	41	4.15	0.041	$1.78 \cdot 10^{-5}$	22	0.055	1.9

^{a)} At 37° and pH 4.5. ^{b)} Only K_i values shown (for the inhibition type see *Tables 1* and *2*). ^{c)} $K_M = 2.3$ mM (mean value of all measurements; cf. *Exper. Part*). ^{d)} No inflection of the titration curve was observed between indicated pH values. ^{e)} No second pK value was observed in the indicated pH range. ^{f)} Taken from [5]. ^{g)} $IC_{50} = 0.60$ μ M [3].

corresponding methyl ester **46** proved a better inhibitor by *ca.* one order of magnitude. Also the tetrazolyl derivative **50** (essentially undissociated at the pH of the assay) is a better inhibitor than the acid, about equipotent to the ester, suggesting a disrupting influence of the negative charge of the carboxylate, perhaps diverting the protonation of the 'glycosidic heteroatom' by the catalytic acid.

To the best of our knowledge, the aniline **35** is the strongest competitive inhibitor of the β -mannosidase from snail, and the 2-phenylethynyl derivative **29** the most potent, albeit non-competitive, inhibitor of this enzyme.

Table 3 shows the data for the inhibition of the α -mannosidase from *Jack* beans. All imidazopyridines proved competitive inhibitors. The selectivity for the inhibition of the β - vs. α -mannosidase range from 1.1 for the carboxylate **47** to 344 for the 2-phenylethynyl derivative **28**. There is no clear correlation of the selectivity with the strength of the inhibition of the β -mannosidase; weaker inhibitors tend to be more selective. For the imidazoles **9**, **32**, **40**, **41**, and **43**, possessing an oxymethylene substituent at C(2), one finds a correlation between the selectivity and the pK value ($R=0.96$), the more strongly basic imidazopyridines being more highly selective¹²). This correlation still holds ($R=0.90$), when the 2-phenylethynyl derivative **29** is included in the comparison, but not when the aniline **35** is included ($R=0.40$). The best inhibitor of the α -mannosidase is the (4-nitrophenoxy)methyl derivative **41** ($K_i=41$ nM).

We thank Dr. B. Schweizer for the determination of the X-ray structure of **18**, M. Schneider and D. Manser for the pK_{HA} determinations, Dr. B. Bernet for checking the experimental part, and the Swiss National Science Foundation and Oxford Glycosciences Ltd., Abingdon (UK), for generous support.

Experimental Part

General. Solvents were distilled before use: THF and toluene from Na, benzophenone and CH_2Cl_2 from P_2O_5 , and DMF from CaH_2 . Reactions were carried out under Ar, unless stated otherwise. Qual. TLC: precoated silica-gel plates (*Merck* silica gel 60 F_{254}); detection by heating with 'mostain' (400 ml of 10% H_2SO_4 soln., 20 g of $(NH_4)_6Mo_7O_{24} \cdot 6 H_2O$, 0.4 g of $Ce(SO_4)_2$). Flash chromatography (FC): silica gel *Fluka* 60 (0.04–0.063 mm). M.p.: uncorrected. Optical rotations: 1-dm cell at 25°, 589 nm. UV Spectra (*ca.* 0.2 mM solns.): in 1-cm cell at 25° in the range of 190 to 500 nm (log ϵ values in parenthesis). FT-IR spectra: KBr or *ca.* 2% soln. in $CHCl_3$, absorption in cm^{-1} . 1H - and ^{13}C -NMR spectra: chemical shifts δ in ppm rel. to TMS as external standard, and coupling constants J in Hz. FAB-MS: in 3-nitrobenzyl alcohol (NOBA) matrix. MALDI- and HR-MALDI-MS: in gentisic acid (=2,5-dihydroxybenzoic acid, DHB) matrix. The pK_{HA} values were determined in H_2O by potentiometric titration with HCl at 25°. $[Pd(OAc)_2(P(2-tolyl)_3)_2]$ was prepared according to [17]. The β -mannosidase from snail acetone powder (EC 3.2.1.25, as a suspension in 3.0M $(NH_4)_2SO_4$ containing 10 mM AcONa, pH *ca.* 4.0, *Sigma M-9400*), α -mannosidase from *Jack* beans (EC 3.2.1.24, as a suspension in 3.0M $(NH_4)_2SO_4$ and 0.1 mM zinc acetate, pH *ca.* 7.5, *Sigma M-7257*), 4-nitrophenyl β -D-mannopyranoside (*Sigma N-1268*), and 4-nitrophenyl α -D-mannopyranoside (*Sigma N-2127*) were used without further purification.

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2,3-diiodoimidazo[1,2-a]pyridine (**18**) and (5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-3-iodoimidazo[1,2-a]pyridine (**19**). *a*) A soln. of **17** (5.34 g, 9.52 mmol) in DMF (60 ml) was treated with *N*-iodosuccinimide (NIS; 21.6 g, 96.0 mmol, 10 equiv.) and stirred under Ar at 80° for 14 h. The brown mixture was cooled, diluted with Et_2O (250 ml), and washed with $Na_2S_2O_3$ (10% aq. soln., 3 \times 150 ml). The combined H_2O layers were extracted with Et_2O (2 \times 100 ml). The combined org. layers were washed with H_2O (150 ml) and

¹²) Among the lactone and lactame oxime-derived inhibitors, the more strongly basic ones proved less selective [55].

brine (150 ml), dried (MgSO₄), filtered, and concentrated *i.v.* FC (cyclohexane/AcOEt 1:0 → 5:1 → 1:3) gave **18** (6.17 g, 80%) as an oil, which crystallized *i.v.* Recrystallisation from AcOEt/hexane gave **18** as white crystals.

b) A soln. of **17** (100 mg, 0.178 mmol) in DMF (1.5 ml) was treated with NIS (136 mg, 0.604 mmol, 3.4 equiv.) and stirred under Ar at 50° for 8 h. After workup and FC (similarly as described in *a*), **19** (68 mg, 56%) and **18** (33 mg, 23%) were obtained.

Data of 18: *R*_f (hexane/AcOEt 5:1) 0.32. M.p. 134.6–135.5°. [α]_D²⁵ = –99.9 (*c* = 1.08, CHCl₃). UV (CHCl₃): 268 (2.98). IR (CHCl₃): 3065w, 2870m, 1953w, 1878w, 1812w, 1603w, 1497w, 1451m, 1358m, 1178w, 1098s, 1026m, 978w, 911w. ¹H-NMR (CDCl₃, 300 MHz): see Table 4; additionally, 4.44 (*d*, *J* = 11.8, PhCH); 4.51 (*d*, *J* = 12.1, PhCH); 4.55 (*d*, *J* = 11.5, PhCH); 4.60 (br. s, PhCH₂); 4.62 (*d*, *J* = 12.1, PhCH); 4.74 (*d*, *J* = 11.8, PhCH); 4.78 (*d*, *J* = 12.5, PhCH); 7.23–7.39 (*m*, 20 arom. H). ¹³C-NMR (CDCl₃, 75 MHz): see Table 5; additionally, 70.66, 70.91 (2*t*, CH₂–C(5), PhCH₂); 72.04 (*t*, PhCH₂); 73.33 (*t*, 2 PhCH₂); 127.78–128.52 (several *d*); 137.39, 137.52, 137.64, 138.08 (4*s*). FAB-MS: 1625 (5, [2*M* + H]⁺), 813 (100, [M + H]⁺), 721 (6, [M – Bn]⁺), 705 (18, [M – BnO]⁺), 685 (5, [M – I]⁺), 579 (9), 493 (6), 91 (83). HR-MALDI-MS: 851.0275 (7, C₃₆H₃₄I₂KN₂O₄, [M + K]⁺; calc. 851.0249), 835.0490 (100, C₃₆H₃₄I₂N₂NaO₄, [M + Na]⁺; calc. 835.0509), 813.0681 (37, C₃₆H₃₅I₂N₂O₄, [M + H]⁺; calc. 813.0690), 709.1560 (30), 705.0119 (92, C₂₀H₂₇I₂N₂O₃, [M – BnO]⁺; calc. 705.0115), 687.1698 (44), 579.1132 (60), 561.2747 (9), 451.2002 (21). Anal. calc. for C₃₆H₃₄I₂N₂O₄ (812.48): C 53.22, H 4.22, N 3.45; found: C 53.45, H 4.37, N 3.63.

Table 4. Selected ¹H-NMR Chemical Shifts [ppm] and Coupling Constants [Hz] of the Protected Imidazoles **18**–**20**, **22**–**27**, and **30** in CDCl₃

	18	19	20	22	23	24	25	26	27	30
H–C(3)	–	–	^{a)}	7.86	7.11	^{a)}	7.20	6.82	7.41	7.19
H–C(5)	4.36	4.41	4.11	4.18	4.09	4.12	4.13	4.06	4.12	4.09
H–C(6)	4.47	4.51	4.26	4.25	4.29	4.24	4.30	4.31	4.26	4.26
H–C(7)	3.75	3.79	3.84	3.88	3.86	3.86	3.90	3.88	3.86	3.88
H–C(8)	4.75	4.79	4.77	4.81	4.79	4.80	4.87	4.80	4.761	4.79
CH–C(5)	3.62	3.68	3.57	3.60	3.60	3.59	3.63	3.59	3.60	3.58
CH'–C(5)	3.72	3.75	3.72	3.73	3.75	3.73	3.77	3.73	3.73	3.73
<i>J</i> (5,6)	2.5	2.2	7.2	6.8	7.5	7.2	7.2	7.2	7.2	7.2
<i>J</i> (6,7)	7.8	7.8	9.3	8.7	9.3	9.3	9.3	9.3	9.3	9.3
<i>J</i> (7,8)	3.1	3.1	3.1	3.1	3.1	3.1	2.8	3.1	3.1	2.8
<i>J</i> (5,CH)	5.0	5.0	7.2	7.2	6.9	7.2	7.2	6.9	7.2	7.2
<i>J</i> (5,CH')	8.7	9.0	3.1	2.8	2.8	3.1	3.1	3.1	3.0	2.8
<i>J</i> (CH,CH')	9.3	9.3	10.3	10.0	10.0	10.0	10.0	10.0	10.1	10.0

^{a)} Hidden by signals of the Ph groups at 7.24–7.42 ppm.

X-Ray Analysis of 18. Orthorhombic *P*2₁2₁2₁; *a* = 11.9793(2), *b* = 14.8025(3), *c* = 19.5612(5); *V* = 3468.66(13) Å³, *D*_{calc} = 1.556 Mg/m³, *Z* = 4. The reflexions were measured on a Bruker Nonius-KappaCCD diffractometer (graphite monochromator, MoK_α radiation, λ = 0.71073) at 298 K. *R* = 0.0535, *R*_w = 0.1541. All calculations were performed using maXus [56]. The non-H-atoms were refined anisotropically with SHELXL-97 [57]. The H-atoms were calculated at idealized positions and included in the structure-factor calculation with fixed isotropic displacement parameters.

Data of 19: *R*_f (hexane/Et₂O 5:1) 0.38. [α]_D²⁵ = –90.2 (*c* = 1.00, CHCl₃). UV (CHCl₃): 285 (2.74), 258 (3.11), 242 (3.80). IR (CHCl₃): 3065w, 2936m, 2870m, 1953w, 1878w, 1812w, 1744w, 1638w, 1603w, 1497m, 1450s, 1357m, 1096s, 1026s, 911m, 833m. ¹H-NMR (CDCl₃, 300 MHz): see Table 4; additionally, 4.49 (*d*, *J* = 11.8, PhCH); 4.53 (*d*, *J* = 12.1, PhCH); 4.55 (*d*, *J* = 11.8, PhCH); 4.57 (*d*, *J* = 11.2, PhCH); 4.61 (*d*, *J* = 11.2, PhCH); 4.65 (*d*, *J* = 12.1, PhCH); 4.78 (*d*, *J* = 12.1, PhCH); 4.82 (*d*, *J* = 12.1, PhCH); 7.15 (s, H–C(2)); 7.26–7.43 (*m*, 20 arom. H). ¹³C-NMR (CDCl₃, 75 MHz): see Table 5; additionally, 70.73, 71.16 (2*t*, CH₂–C(5), PhCH₂); 72.07, 73.40, 73.46 (3*t*, 3 PhCH₂); 127.94–128.65 (several *d*); 137.77, 137.92, 138.03, 138.45 (4*s*). HR-MALDI-MS: 725.1251 (4, C₃₆H₃₅IKN₂O₄, [M + K]⁺; calc. 725.1280), 709.1534 (83, C₃₆H₃₅IN₂NaO₄, [M + Na]⁺; calc. 709.1541), 687.1715 (62, C₃₆H₃₆IN₂O₄, [M + H]⁺; calc. 687.1721), 579.1141 (87, C₂₀H₂₈IN₂O₃, [M – BnO]⁺; calc. 579.1146), 561.2756

Table 5. Selected ^{13}C -NMR Chemical Shifts [ppm] of the Protected Imidazoles **18**–**20**, **22**–**27**, **30**, **31**, **34**, **36**–**39**, **44**, **45**, **48**, and **49** in CDCl_3

Compound	C(2)	C(3)	C(5)	$\text{CH}_2\text{-C}(5)$	C(6)	C(7)	C(8)	C(8a)
18	96.30	82.51	62.60	^{a)}	77.61	80.39	68.69	148.71
19	136.98	69.93	60.99	^{a)}	77.99	80.92	68.74	146.80
20	82.17	125.04	60.10	^{a)}	73.75	79.79	68.22	145.08
22	142.00	125.95	60.47	^{a)}	73.67	79.47	68.55	145.04
23	142.11	116.65	59.80	70.80	73.92	80.06	68.63	143.05
24	127.95–128.93	122.33	60.14	^{a)}	74.03	79.83	68.19	144.72
25	140.48	^{b)}	59.89	^{a)}	74.03	80.03	68.46	143.34
26	^{b)}	115.38	59.68	^{a)}	74.14	80.29	68.79	^{b)}
27^{c)}	124.30	123.48	60.09	70.78	73.82	79.87	68.33	143.20
30	137.67–138.80	118.54	59.99	^{a)}	74.00	80.18	68.76	143.57
31^{c)}	138.17	118.33	59.84	70.74	73.93	80.06	68.63	142.99
34^{c)}	140.29	116.39	59.81	70.77	74.04	80.13	68.79	142.78
36	137.01	118.43	59.92	^{a)}	73.89	79.91	68.43	142.76
37	136.86	119.23	60.10	70.99	73.99	80.05	68.83	143.61
38	135.61	119.48	59.89	^{a)}	73.68	79.58	68.39	143.23
39	136.78	118.71	59.92	^{a)}	73.84	79.89	68.56	143.26
44	133.35	125.78	60.42	^{a)}	73.76	79.97	68.45	143.99
45	133.77	125.71	60.34	^{a)}	73.79	79.99	68.75	144.05
48	114.11–114.76	127.72–128.52	60.48	^{a)}	73.41	78.95	67.81	144.65
49	126.85	121.31	60.78	^{a)}	73.20	78.86	67.50	145.63

^{a)} Two *t* for $\text{CH}_2\text{-C}(5)$ and a PhCH_2 at 70.07–71.45 ppm. ^{b)} Not assigned. ^{c)} Assignments based on HSQC-GRASP spectrum.

(100), 453.2174 (57). Anal. calc. for $\text{C}_{36}\text{H}_{35}\text{IN}_2\text{O}_4$ (686.58): C 62.98, H 5.14, N 4.08; found: C 63.04, H 5.25, N 4.09.

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2-iodoimidazo[1,2-a]pyridine (**20**). EtMgBr soln. in THF (1M, 7.5 ml, 7.50 mmol) was added dropwise to a stirred soln. of **18** (5.11 g, 6.29 mmol) in freshly distilled THF (60 ml) at 23° for 10 min. After 25 min, the mixture was treated with sat. NH_4Cl soln. (50 ml) and diluted with Et_2O (100 ml). The layers were separated, and the org. layer was washed with sat. NH_4Cl soln. (2×50 ml). The combined H_2O layers were extracted with Et_2O (2×40 ml). The combined org. layers were washed with H_2O (70 ml) and brine (70 ml), dried (MgSO_4), filtered, and evaporated. FC (hexane/AcOEt 1:0 \rightarrow 8:1 \rightarrow 5:1 \rightarrow 1:1) gave **20** (3.82 g, 88%) and **17** (0.36 g, 10%) as oils.

Data of **20**: R_f (hexane/AcOEt 1:1) 0.62. $[\alpha]_{\text{D}}^{25} = -37.5$ ($c = 0.98$, CHCl_3). IR (CHCl_3): 3065w, 2869m, 1954w, 1879w, 1813w, 1728w, 1602w, 1495m, 1454m, 1427w, 1363m, 1256w, 1112s, 1026s, 946w, 914w. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): see Table 4; additionally, 4.46 (br. s, PhCH_2); 4.60 (*d*, $J = 12.1$, PhCH); 4.61 (*d*, $J = 11.2$, PhCH); 4.66 (*d*, $J = 12.1$, PhCH); 4.67 (*d*, $J = 11.8$, PhCH); 4.75 (*d*, $J \approx 12.8$, PhCH); 4.99 (*d*, $J = 11.2$, PhCH); 7.24–7.42 (*m*, 20 arom. H, $\text{H-C}(3)$). $^{13}\text{C-NMR}$ (CDCl_3 , 75 MHz): see Table 5; additionally, 70.63, 70.79, (*2t*, $\text{CH}_2\text{-C}(5)$, PhCH_2); 71.86, 73.23 (*2t*, 2 PhCH_2); 75.00 (*t*, PhCH_2); 127.61–128.58 (several *d*); 137.33, 137.69, 137.87, 137.98 (4s). FAB-MS: 1373 (5, $[2M + 1]^+$), 687 (100, $[M + 1]^+$), 579 (14), 473 (6), 367 (5), 91 (51). HR-MALDI-MS: 709.1563 (48, $\text{C}_{36}\text{H}_{35}\text{IN}_2\text{NaO}_4$, $[M + \text{Na}]^+$; calc. 709.1541), 687.1705 (100, $\text{C}_{36}\text{H}_{36}\text{IN}_2\text{O}_4$, $[M + \text{H}]^+$; calc. 687.1721), 579.1149 (73, $\text{C}_{29}\text{H}_{28}\text{IN}_2\text{O}_3$, $[M - \text{BnO}]^+$; calc. 579.1146), 561.2750 (27), 453.2167 (16). Anal. calc. for $\text{C}_{36}\text{H}_{35}\text{IN}_2\text{O}_4$ (686.58): C 62.98, H 5.14, N 4.08; found: C 62.89, H 5.27, N 3.97.

(5R,6R,7S,8R)-5-(Hydroxymethyl)-5,6,7,8-tetrahydro-3-iodoimidazo[1,2-a]pyridine-6,7,8-triol (**21**). A soln. of **19** (35 mg, 51.0 μmol) in CH_2Cl_2 (1.5 ml) was treated at -78° with 1M BCl_3 soln. in CH_2Cl_2 (0.9 ml, 0.90 mmol), stirred until the mixture had reached a temp. of 15° (ca. 5 h), cooled to -78° , and treated with H_2O (2 ml). After evaporation, FC (AcOEt/MeOH 10:1 \rightarrow 5:1) and lyophilisation gave **21** (9.3 mg, 56%) as a colourless hygroscopic resin. R_f (AcOEt/MeOH 5:1) 0.11. $[\alpha]_{\text{D}}^{25} = -39.0$ ($c = 0.70$, MeOH). UV (MeOH): 223 (3.63). IR (KBr): 3600–2400s (br.), 2921m, 1632w, 1523w, 1443m, 1340w, 1273w, 1177m, 1130w, 1077s, 979w, 937w, 899w. $^1\text{H-NMR}$ (CD_3OD , 300 MHz): 3.90 (*dd*, $J = 6.5$, 14.3, $\text{CH-C}(5)$); 3.91 (*dd*, $J = 4.1$, 6.2, irradiated).

Table 6. Selected ^{13}C -NMR Chemical Shifts [ppm] of the Deprotected Imidazoles **9**–**13**, **21**, **28**, **29**, **32**, **35**, **40**, **41**, **43**, **46**, **47**, and **50** in CD_3OD

Compound	C(2)	C(3)	C(5)	$\text{CH}_2\text{-C}(5)$	C(6)	C(7)	C(8)	C(8a)
9 ^{a)}	143.65	118.80	63.63	62.11	67.34	73.63	66.55	147.91
10	^{c)}	115.62	63.44	62.95	67.06	73.15	65.69	145.79
11	141.78	115.96	63.61	62.94	67.15	73.17	65.71	146.32
12 ^{a)}	136.30	115.72	61.83 ^{b)}	59.32	65.08	69.29	62.26 ^{b)}	142.71
13	81.61	125.38	64.07	62.90	67.31	72.66	66.35	149.18
21	136.95	69.86	64.83	63.26	70.43	72.79	66.05	150.51
28	^{c)}	123.61	64.04	62.95	67.09	72.81	65.55	147.23
29	141.09	^{c)}	63.80	62.94	67.08	73.00	65.75	147.20
32	138.71	118.62	63.76	63.00	67.10	73.01	65.68	146.83
35 ^{a)}	139.70	115.36	60.77	59.22	64.48 ^{b)}	70.81	63.71 ^{b)}	147.31
40	141.75	^{c)}	63.22 ^{b)}	62.15	69.11 ^{b)}	70.13 ^{b)}	64.04 ^{b)}	147.47
41	137.68	119.47	63.86	63.07	67.16	73.01	65.72	147.37
43	137.72	119.17	63.82	63.05	67.12	72.98	65.69	147.13
46	133.49	126.01	64.25	62.98	67.05	72.70	65.62	148.42
47 ^{a)}	137.70	121.84	61.55	59.56	64.74 ^{b)}	70.79	63.90 ^{b)}	145.42
50 ^{a)}	131.48	116.70	61.14	59.30	64.51 ^{b)}	70.76	63.81 ^{b)}	145.92

^{a)} Measured in D_2O . ^{b)} Assignment may be interchanged. ^{c)} Not assigned.

4.45 \rightarrow *d*, $J = 4.1$, irradi. at 4.80 \rightarrow *d*, $J = 6.2$, $\text{H-C}(7)$; 4.14 (*dd*, $J = 7.2$, 14.3, $\text{CH}'\text{-C}(5)$); 4.11–4.17 (*m*, irradi. at 4.45 \rightarrow change, $\text{H-C}(5)$); 4.45 (*dd*, $J = 2.2$, 6.2, $\text{H-C}(6)$); 4.80 (*d*, $J = 3.7$, $\text{H-C}(8)$); 7.10 (*s*, $\text{H-C}(2)$). ^{13}C -NMR (CD_3OD , 75 MHz): see Table 6. HR-MALDI-MS: 326.9830 (100, $\text{C}_8\text{H}_{12}\text{IN}_2\text{O}_4$, $[\text{M} + \text{H}]^+$; calc. 326.9844).

(5*R*,6*R*,7*S*,8*R*)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-iodoimidazo[1,2-*a*]pyridine-6,7,8-triol (**13**). A soln. of **20** (100 mg, 0.146 mmol) in CH_2Cl_2 (4 ml) was treated at -78° with 1*M* BCl_3 soln. in CH_2Cl_2 (2.5 ml, 2.50 mmol), stirred until the mixture had reached a temp. of 15° (ca. 5 h), cooled to -78° , and treated with H_2O (3 ml). After evaporation, FC (AcOEt/MeOH 10:1), ion-exchange chromatography (Amberlite CG-120, H^+ form, elution with 0.1*M* aq. NH_3), and lyophilisation gave **13** (30.6 mg, 64%). Colourless hygroscopic resin. R_f (AcOEt/MeOH 5:1) 0.20. $[\alpha]_{\text{D}}^{25} = -16.5$ ($c = 0.47$, MeOH). UV (MeOH): 226 (3.56), 206 (3.76). IR (KBr): 3600–2400s (br.), 2925*m*, 2852*w*, 1695*w*, 1632*m*, 1485*w*, 1432*m*, 1382*m*, 1337*m*, 1259*w*, 1223*m*, 1176*w*, 1098*m*, 1004*w*, 957*w*, 903*w*, 635*w*. ^1H -NMR (CD_3OD , 300 MHz): 3.80 (*dd*, $J = 3.7$, 9.0, irradi. at 4.09 \rightarrow br. *d*, $J \approx 3.4$, irradi. at 4.79 \rightarrow *d*, $J = 9.0$, $\text{H-C}(7)$); 3.87 (*dd*, $J = 5.6$, 13.4, $\text{CH-C}(5)$); 3.85–3.92 (*m*, irradi. at 4.09 \rightarrow change, $\text{H-C}(5)$); 4.09 (*dd*, $J = 7.2$, 9.3, irradi. at 3.80 \rightarrow br. *d*, $J \approx 6.2$, $\text{H-C}(6)$); 4.13 (*dd*, $J = 5.3$, 13.4, $\text{CH}'\text{-C}(5)$); 4.79 (*d*, $J = 3.7$, irradi. at 3.80 \rightarrow *s*, $\text{H-C}(8)$); 7.44 (*s*, $\text{H-C}(3)$). ^{13}C -NMR (CD_3OD , 75 MHz): see Table 6. HR-MALDI-MS: 326.9838 (100, $\text{C}_8\text{H}_{12}\text{IN}_2\text{O}_4$, $[\text{M} + \text{H}]^+$; calc. 326.9844).

(5*R*,6*R*,7*S*,8*R*)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyridine-2-carbaldehyde (**22**). A soln. of **20** (320 mg, 0.466 mmol, dried for 1 week *i.v.* over P_2O_5 ¹³) in THF (6.5 ml) was treated at -35° with 1*M* EtMgBr soln. in THF (940 μl , 0.940 mmol), stirred under Ar at -35° for 10 min and at 23° for 10 min. The mixture was cooled to -35° , treated with DMF (600 μl , 7.80 mmol), and stirred at -35° to 23° for 3 h. The mixture was treated with H_2O (10 ml), diluted with Et_2O (60 ml), and washed with sat. NH_4Cl soln. (3×30 ml). The combined aq. layers were extracted with Et_2O (2×30 ml). The combined org. layers were washed with H_2O (40 ml) and brine (40 ml), dried (MgSO_4), filtered, and evaporated. FC (hexane/AcOEt 2:1 \rightarrow 1:1) gave **22** (234 mg, 85%) as an oil, which crystallized *i.v.*, and **17** (18 mg, 7%) as an oil.

Data of **22**: R_f (hexane/AcOEt 1:1) 0.29. $[\alpha]_{\text{D}}^{25} = -48.6$ ($c = 1.17$, CHCl_3). UV (CHCl_3): 278 (3.34). IR (CHCl_3): 3150*w*, 3065*w*, 3008*m*, 2868*m*, 1954*w*, 1878*w*, 1812*w*, 1689*s*, 1604*w*, 1537*m*, 1497*w*, 1454*m*, 1364*m*, 1257*w*, 1106*s*, 1025*m*, 914*w*. ^1H -NMR (CDCl_3 , 300 MHz): see Table 4; additionally, 4.44 (*d*, $J = 12.1$, PhCH); 4.48 (*d*, $J = 12.1$, PhCH); 4.61 (*d*, $J = 11.8$, PhCH); 4.62 (*d*, $J = 11.2$, PhCH); 4.68 (*d*, $J = 12.5$, 2 PhCH); 4.78 (*d*, $J = 12.5$, PhCH); 4.96 (*d*, $J = 11.5$, PhCH); 7.23–7.28 (*m*, 4 arom. H); 7.29–7.38 (*m*, 14 arom. H); 7.39–7.43 (*m*, 2 arom. H); 9.88 (*s*, CHO). ^{13}C -NMR (CDCl_3 , 75 MHz): see Table 5; additionally, 70.48, 71.03 (2*t*, PhCH₂,

¹³⁾ Required to secure reproducible yields of **22** (80–90%).

CH₂–C(5)); 72.06 (*t*, PhCH₂); 73.33 (*t*, PhCH₂); 74.83 (*t*, PhCH₂); 127.76–128.60 (several *d*); 137.10, 137.55, 137.66, 137.68 (4*s*); 185.79 (*d*, CHO). HR-MALDI-MS: 611.2509 (65, C₃₇H₃₆N₂NaO₅, [M + Na]⁺; calc. 611.2522), 589.2688 (100, C₃₇H₃₇N₂O₅, [M + H]⁺; calc. 589.2702), 481.2132 (53, C₃₀H₂₉N₂O₄, [M – BnO]⁺; calc. 481.2127), 453.2179 (17, C₂₉H₂₉N₂O₃, [M – BnO – CO]⁺; calc. 453.2178). Anal. calc. for C₃₇H₃₆N₂O₅ (588.70): C 75.49, H 6.16, N 4.76; found: C 75.53, H 6.35, N 4.68.

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyridine-2-methanol (**23**). *a*) A soln. of **22** (100 mg, 0.170 mmol) in THF (6 ml) was treated at 23° with LiAlH₄ (65 mg, 1.71 mmol) and stirred for 30 min. The mixture was treated with MeOH/H₂O (4:1, 5 ml). The suspension was filtered through *Celite*, and the residue was washed with Et₂O (80 ml). The filtrate was washed with sat. NH₄Cl soln. (3 × 30 ml), and the combined aq. layers were extracted with Et₂O (2 × 20 ml). The combined org. layers were washed with H₂O (60 ml) and brine (60 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 1:1 → 0:1) gave **23** (85 mg, 85%). Colourless oil.

b) At 23°, a soln. of **22** (95 mg, 0.161 mmol) in EtOH (6 ml) was treated with NaBH₄ (12 mg, 0.317 mmol), stirred for 30 min, and evaporated. Workup and FC (as described in *a*) gave **23** (85 mg, 89%).

Data of 23: R_f (AcOEt) 0.15. [α]_D²⁵ = –33.7 (*c* = 0.96, CHCl₃). UV (CHCl₃): 266 (3.21). IR (CHCl₃): 3400*w*, 3160*w*, 3066*w*, 3008*m*, 2929*m*, 2870*m*, 1954*w*, 1878*w*, 1812*w*, 1729*w*, 1603*w*, 1498*m*, 1454*m*, 1364*m*, 1258*m*, 1101*s*, 1025*s*, 913*w*. ¹H-NMR (CDCl₃, 300 MHz): see *Table 4*; additionally, 3.30–3.47 (br. *s*, exchange with CD₃OD, OH); 4.45 (br. *s*, PhCH₂); 4.58–4.62 (*m*, irradi. at 3.38 → change, CH₂OH); 4.59 (*d*, *J* = 11.8, PhCH); 4.60 (*d*, *J* = 11.2, PhCH); 4.67 (*d*, *J* = 11.8, PhCH); 4.68 (*d*, *J* = 12.1, PhCH); 4.75 (*d*, *J* = 12.1, PhCH); 5.00 (*d*, *J* = 11.2, PhCH); 7.23–7.35 (*m*, 18 arom. H); 7.36–7.41 (*m*, 2 arom. H). ¹³C-NMR (CDCl₃, 75 MHz): see *Table 5*; additionally, 58.49 (*t*, CH₂–C(2)); 70.80 (2*t*, PhCH₂, CH₂–C(5)); 71.76 (*t*, PhCH₂); 73.18 (*t*, PhCH₂); 74.94 (*t*, PhCH₂); 127.49–128.51 (several *d*); 137.48, 137.81, 137.97, 138.21 (4*s*). HR-MALDI-MS: 613.2673 (37, C₃₇H₃₈N₂NaO₅, [M + Na]⁺; calc. 613.2678), 591.2848 (100, C₃₇H₃₉N₂O₅, [M + H]⁺; calc. 591.2859), 483.2296 (32, C₃₀H₃₁N₂O₂, [M – BnO]⁺; calc. 483.2284), 453.2183 (14, C₂₉H₂₉N₂O₃, [M – BnO – CH₂O]⁺; calc. 453.2178), 375.1714 (11), 359.1761 (11). Anal. calc. for C₃₇H₃₈N₂O₅ (590.72): C 75.23, H 6.48, N 4.74; found: C 75.16, H 6.58, N 4.70.

(5R,6R,7S,8R)-5,6,7,8-Tetrahydro-2,5-bis(hydroxymethyl)imidazo[1,2-*a*]pyridine-6,7,8-triol (**9**). A soln. of **23** (70 mg, 0.119 mmol) in CH₂Cl₂ (3 ml) was treated at –78° with 1*M* BCl₃ in CH₂Cl₂ (1.5 ml, 1.5 mmol), stirred until the mixture had reached a temp. of 10° (*ca.* 4 h), cooled to –78°, treated with H₂O (3 ml), neutralised with sat. NaHCO₃ soln. (10 ml), and evaporated. The residue was taken up in H₂O (3 ml) and applied to ion-exchange column (*Amberlite CG-120*, H⁺ form, elution with 0.1*M* aq. NH₃). Lyophilisation gave **9** (26.5 mg, 97%). Colourless hygroscopic resin. R_f (AcOEt/MeOH 2:1) 0.13. [α]_D²⁵ = –41.1 (*c* = 1.00, H₂O). UV (MeOH): 220 (3.74). IR (KBr): 3600–2400*s* (br.), 2926*m*, 2879*m*, 1642*m*, 1572*w*, 1512*m*, 1456*m*, 1412*m*, 1381*m*, 1320*m*, 1213*m*, 1178*m*, 1095*s*, 1062*s*, 1029*m*, 995*s*, 901*m*. ¹H-NMR (D₂O, 300 MHz): 3.91 (*dt*, *J* = 3.1, 7.8, irradi. at 4.00 → change, H–C(5)); 3.93 (*dd*, *J* = 4.0, 10.0, irradi. at 4.87 → *d*, *J* = 10.3, H–C(7)); 4.00 (*dd*, *J* = 3.1, 12.8, CH–C(5)); 4.18 (*dd*, *J* = 8.1, 10.3, irradi. at 3.93 → change, H–C(6)); 4.19 (*dd*, *J* ≈ 3.1, 13.4, irradi. at 4.00 → br. *d*, *J* ≈ 4.4, CH'–C(5)); 4.48 (br. *s*, CH₂–C(2)); 4.87 (*d*, *J* = 3.7, irradi. at 3.93 → *s*, H–C(8)); 7.24 (*s*, H–C(3)). ¹³C-NMR (D₂O, 75 MHz): see *Table 6*; additionally, 59.59 (*t*, CH₂–C(2)). HR-MALDI-MS: 253.0802 (56, C₉H₁₄N₂NaO₅, [M + Na]⁺; calc. 253.0802), 231.0979 (100, C₉H₁₅N₂O₅, [M + H]⁺; calc. 231.0981), 213.0876 (59, C₉H₁₃N₂O₄, [M – OH]⁺; calc. 213.0876).

*Methyl (E)-3-[(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyridin-2-yl]-prop-2-enoate (24)*. *a*) At 23°, a suspension of **20** (50.9 mg, 74.1 μmol), Pd(OAc)₂ (5.9 mg, 26.3 μmol), PPh₃ (7.5 mg, 28.6 μmol), and Et₃N (16 μl, 0.115 mmol) in freshly distilled and degassed DMF (1 ml) was treated with methyl acrylate (10 μl, 0.111 mmol) and heated to 90° for 15 h. The mixture was diluted with Et₂O (10 ml) and washed with sat. NaHCO₃ soln. (3 × 10 ml). The combined aq. layers were extracted with Et₂O (2 × 10 ml). The combined org. layers were washed with H₂O (15 ml) and brine (15 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 1:0 → 9:1 → 7:3 → 1:1) gave **24** (25.8 mg, 54%) and **17** (4.5 mg, 11%). Oils.

b) A suspension of **20** (115 mg, 0.168 mmol), [Pd(OAc)₂(P(2-tolyl)₃)₂] (11.6 mg, 11.9 μmol) and K₂CO₃ (65 mg, 0.656 mmol) in freshly distilled and degassed DMF (2 ml) was treated with methyl acrylate (0.2 ml, 2.22 mmol) and heated to 90° for 165 min. Workup and FC, as described in *a*, gave **24** (101.6 mg, 94%).

Data of 24: R_f (hexane/AcOEt 3:1) 0.16. [α]_D²⁵ = –42.2 (*c* = 0.90, CHCl₃). UV (CHCl₃): 328 (2.73). IR (CHCl₃): 3148*w*, 3065*w*, 2950*m*, 2869*m*, 1953*w*, 1878*w*, 1812*w*, 1705*s*, 1643*s*, 1497*w*, 1447*m*, 1364*m*, 1301*m*, 1271*s*, 1168*s*, 1109*s*, 1025*s*, 981*m*, 914*w*. ¹H-NMR (CDCl₃, 300 MHz): see *Table 4*; additionally, 3.79 (*s*, MeO); 4.46 (br. *s*, PhCH₂); 4.57 (*d*, *J* = 12.1, PhCH); 4.62 (*d*, *J* = 12.1, PhCH); 4.66 (*d*, *J* = 12.1, PhCH); 4.69 (*d*, *J* = 12.1, PhCH); 4.77 (*d*, *J* = 11.2, PhCH); 4.99 (*d*, *J* = 11.2, PhCH); 6.60 (*d*, *J* = 15.6, CH=CH–C(2)); 7.25–7.38 (*m*, 18 arom. H).

H–C(3)); 7.42–7.45 (*m*, 2 arom. H); 7.56 (*d*, $J = 15.6$, CH=CH–C(2)). $^{13}\text{C-NMR}$ (CDCl_3 , 75 MHz): see Table 5; additionally, 51.61 (*q*, MeO); 70.77, 70.98 (2*t*, PhCH₂, CH₂–C(5)); 71.92 (*t*, PhCH₂); 73.42 (*t*, PhCH₂); 75.02 (*t*, PhCH₂); 115.94 (*d*, CH=CH–C(2)); 127.95–128.83 (several *d*, including C(2)); 136.72 (*d*, CH=CH–C(2)); 137.56, 137.90, 138.08, 138.37 (4*s*); 168.43 (*s*, C=O). FAB-MS: 1289 (3, [2*M* + 1]⁺), 645 (100, [M + 1]⁺), 537 (11), 431 (9), 220 (7), 91 (77). Anal. calc. for C₄₀H₄₀N₂O₆ (644.77): C 74.51, H 6.25, N 4.34; found: C 74.69, H 6.30, N 4.28.

(5*R*,6*R*,7*S*,8*R*)-6,7,8-*Tris*(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2-[(*E*)-2-phenylethenyl]-imidazo[1,2-*a*]pyridine (**25**). *a*) A suspension of **20** (31 mg, 45.2 μmol), Pd(OAc)₂ (1.5 mg, 6.68 μmol), PPh₃ (3.0 mg, 11.4 μmol), and K₂CO₃ (9.5 mg, 68.7 μmol) in degassed DMF (0.7 ml) was treated with styrene (0.1 ml, 0.87 mmol), and stirred at 80° for 16 h, cooled to r.t., diluted with Et₂O (15 ml), and washed with sat. NH₄Cl soln. (3 × 10 ml). The combined aq. layers were extracted with Et₂O (2 × 5 ml). The combined org. layers were washed with H₂O (10 ml) and brine (10 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 1:0 → 7:1 → 1:1 → 1:2) gave **17** (5.0 mg, 20%) as an oil, and **25/20** (17 mg, *ca.* 3:2). HPLC (hexane/Et₂O 3:1) of this mixture gave **25** (7.6 mg, 25%) and **20** (5.6 mg, 18%) as yellowish oils.

b) As described in *a*, but with [Pd(OAc)₂(P(2-tolyl)₃)₂] instead of Pd(OAc)₂ and PPh₃. Compounds **17** (2%), **25** (45%), and **20** (23%) were isolated as oils.

c) As described in *a*, but in DMF/H₂O 6:1 instead of DMF. After workup, FC and HPLC gave **17** (5%), **25** (24%), and **20** (25%).

d) As described in *c*, but with [Pd(OAc)₂(P(2-tolyl)₃)₂] instead of Pd(OAc)₂ and PPh₃; workup gave **17** (13%), **25** (18%), and **20** (30%).

e) A soln. of **22** (40 mg, 67.947 μmol) and diethyl benzylphosphonate (43 μl, 0.2063 mmol) in THF (1.3 ml) was treated at 0° with 1*M* soln. of *t*-BuOK in THF (0.20 ml, 0.20 mmol) and stirred at 0° for 5 min. The mixture was treated with sat. NH₄Cl soln. (3 ml). The mixture was diluted with CH₂Cl₂ (25 ml) and washed with sat. NH₄Cl soln. (25 ml). The aq. layer was extracted with CH₂Cl₂ (2 × 25 ml). The combined org. extracts were washed with brine (40 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 5:1) gave **25** (39.3 mg, 87%). Colourless oil.

Data of 25: R_f (hexane/AcOEt 4:1) 0.26. $[\alpha]_D^{25} = -32.8$ ($c = 1.00$, CHCl₃). UV (CHCl₃): 311 (4.37), 302 (4.37), 239 (3.99). IR (CHCl₃): 3150*w*, 3067*w*, 3033*m*, 3013*m*, 2929*m*, 2869*m*, 1950*w*, 1877*w*, 1812*w*, 1644*w*, 1599*w*, 1535*w*, 1497*m*, 1455*m*, 1364*m*, 1343*m*, 1266*w*, 1113*s*, 1028*m*, 963*m*, 910*m*. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): see Table 4; additionally, 4.48 (br. *s*, PhCH₂); 4.62 (*d*, $J = 12.1$, PhCH); 4.63 (*d*, $J = 11.2$, PhCH); 4.71 (*d*, $J = 12.1$, PhCH); 4.74 (*d*, $J = 11.8$, PhCH); 4.81 (*d*, $J = 12.1$, PhCH); 5.02 (*d*, $J = 11.2$, PhCH); 6.99 (*d*, $J = 16.2$, C(2)–CH=CH); 7.22–7.38 (*m*, 21 arom. H, C(2)–CH=CH); 7.41–7.45 (*m*, 2 arom. H); 7.49–7.52 (*m*, 2 arom. H). $^{13}\text{C-NMR}$ (CDCl_3 , 75 MHz): see Table 5; additionally, 70.62, 70.92 (2*t*, CH₂–C(5), PhCH₂); 71.67 (*t*, PhCH₂); 73.18 (*t*, PhCH₂); 74.89 (*t*, PhCH₂); 117.61 (*d*); 120.23 (*d*); 126.21 (2*d*); 127.06 (2*d*); 127.51 (*d*); 127.73–128.55 (several *d*); 137.45, 137.66, 137.74, 137.96, 138.10 (5*s*). MALDI-MS: 1327 ([2*M* + H]⁺), 663 ([M + H]⁺). HR-MALDI-MS: 685.3043 (14, C₄₄H₄₂N₂NaO₄, [M + Na]⁺; calc. 685.3042), 663.3209 (100, C₄₄H₄₃N₂O₄, [M + H]⁺; calc. 663.3223), 555.2633 (40, C₃₇H₃₅N₂O₃, [M – BnO]⁺; calc. 555.2647). Anal. calc. for C₄₄H₄₂N₂O₄ (662.83): C 79.73, H 6.39, N 4.23; found: C 79.85, H 6.55, N 4.29.

(5*R*,6*R*,7*S*,8*R*)-6,7,8-*Tris*(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2-(2-phenylethyl)imidazo[1,2-*a*]pyridine (**26**). *a*) A soln. of **25** (25 mg, 37.7 μmol) in AcOEt/MeOH/AcOH 1:1:1 (1.5 ml) was treated with 10% Pd/C (12 mg) and hydrogenated for 96 h at 6 bar. Filtration over *Celite*, evaporation and FC (hexane/AcOEt 2:1) gave **26** (12 mg, 48%). Colourless oil.

b) A soln. of **25** (22 mg, 33.2 μmol) in AcOEt (1 ml) was treated with 10% Pd/C (10 mg) and hydrogenated for 6 h at 6 bar. Workup and FC as described in *a* gave **26** (16.5 mg, 75%). R_f (hexane/AcOEt 2:1) 0.18. $[\alpha]_D^{25} = -32.3$ ($c = 1.03$, CHCl₃). UV (CHCl₃): 241 (3.69). IR (CHCl₃): 3088*w*, 3066*w*, 3031*m*, 3012*m*, 2928*m*, 2865*m*, 1951*w*, 1875*w*, 1810*w*, 1726*w*, 1603*w*, 1585*w*, 1559*w*, 1497*m*, 1454*s*, 1363*m*, 1315*w*, 1267*w*, 1207*w*, 1171*w*, 1099*s*, 1027*s*, 913*m*. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): see Table 4; additionally, 2.83–2.99 (*m*, CH₂CH₂); 4.41 (*d*, $J = 12.1$, PhCH); 4.46 (*d*, $J = 12.1$, PhCH); 4.62 (*d*, $J = 11.2$, PhCH); 4.64 (*d*, $J = 11.8$, PhCH); 4.68 (*d*, $J = 11.5$, PhCH); 4.71 (*d*, $J = 11.8$, PhCH); 4.76 (*d*, $J = 12.1$, PhCH); 5.01 (*d*, $J = 11.2$, PhCH); 7.13–7.21 (*m*, 2 arom. H); 7.22–7.40 (*m*, 23 arom. H). $^{13}\text{C-NMR}$ (CDCl_3 , 75 MHz): see Table 5; additionally, 30.46, 35.90 (2*t*, CH₂CH₂); 70.53, 70.83 (2*t*, CH₂–C(5), PhCH₂); 71.65 (*t*, PhCH₂); 73.12 (*t*, PhCH₂); 74.92 (*t*, PhCH₂); 125.67 (*d*, C(4) of Ph); 127.26 (*d*); 127.58–128.32 (several *d*); 137.45, 137.76, 137.94, 138.23 (4*s*); 141.90, 141.93, 142.18 (3*s*, C(2), C(8*a*), C(1) of Ph). HR-MALDI-MS: 687.3209 (13, C₄₄H₄₄N₂NaO₄, [M + Na]⁺; calc. 687.3199), 665.3381 (100, C₄₄H₄₅N₂O₄, [M + H]⁺; calc. 665.3379), 557.2803 (24, C₃₇H₃₇N₂O₃, [M – BnO]⁺; calc. 557.2804), 537.2750 (76).

Methyl 3-[(5R,6R,7S,8R)-5,6,7,8-Tetrahydro-6,7,8-trihydroxy-5-(hydroxymethyl)imidazo[1,2-a]pyridin-2-yl]-propanoate (**11**). A soln. of **24** (117 mg, 0.181 mmol) in AcOEt/MeOH/AcOH 1:1:1 (2.4 ml) was treated

with 10% Pd/C (100 mg), hydrogenated for 41 h at 6 bar, and filtered over *Celite* (washing with 25 ml of MeOH/H₂O 9:1). Evaporation, FC (AcOEt/MeOH/H₂O 15:1:1 → 7:1:1), and drying gave **11** (45.7 mg, ca. 88%) as a colourless solid containing substantial amounts of H₂O. The sample for microanalysis was dried for 4 d at 10⁻⁴ Torr. *R*_f (AcOEt/MeOH/H₂O 7:1:1) 0.11. [α]_D²⁵ = -22.1 (*c* = 1.01, MeOH). UV (MeOH): 224 (3.71). IR (KBr): 3600–2400s (br.), 2946m, 2926m, 2851m, 1738s, 1717s, 1635w, 1565w, 1505w, 1442s, 1370m, 1330m, 1260m, 1202m, 1176s, 1098s, 1059s, 1008m, 904m, 837w, 792m. ¹H-NMR (CD₃OD, 300 MHz): 2.61–2.68 (*m*, 2 H), 2.79–2.86 (*m*, 2 H) (CH₂CH₂); 3.65 (*s*, MeO); 3.77 (*dd*, *J* = 3.7, 9.3, irradi. at 4.79 → *d*, *J* = 9.3, H–C(7)); 3.80 (*ddd*, *J* = 2.8, 5.3, 7.8, irradi. at 4.15 → change, H–C(5)); 3.88 (*dd*, *J* = 5.3, 11.8, irradi. at 4.15 → br. *d*, *J* ≈ 4.7, CH–C(5)); 4.09 (*dd*, *J* = 7.8, 9.3, irradi. at 3.77 → br. *d*, *J* ≈ 6.9, H–C(6)); 4.15 (*dd*, *J* = 2.8, 11.8, irradi. at 3.88 → br. *d*, *J* ≈ 3.7, CH'–C(5)); 4.79 (*d*, *J* = 3.7, irradi. at 3.77 → *s*, H–C(8)); 7.09 (*s*, H–C(3)). ¹³C-NMR (CD₃OD, 75 MHz): see Table 6; additionally, 24.43, 34.65 (2*t*, CH₂CH₂); 52.14 (*q*, MeO); 175.17 (*s*, C=O). HR-MALDI-MS: 325.0795 (2, C₁₂H₁₈KN₂O₆, [*M* + *K*]⁺; calc. 325.0802), 309.1052 (77, C₁₂H₁₈N₂NaO₆, [*M* + *Na*]⁺; calc. 309.1062), 287.1233 (100, C₁₂H₁₉N₂O₆, [*M* + *H*]⁺; calc. 287.1243), 269.1133 (14, C₁₂H₁₇N₂O₅, [*M* – *OH*]⁺; calc. 269.1137), 255.0973 (3, C₁₁H₁₅N₂O₅, [*M* – MeO]⁺; calc. 255.0981), 237.0868 (11, C₁₁H₁₃N₂O₄, [*M* – *OH* – MeOH]⁺; calc. 237.0875). Anal. calc. for C₁₂H₁₈N₂O₆ · 0.6 H₂O (297.09): C 48.51, H 6.51, N 9.43; found: C 48.40, H 6.22, N 9.12.

3-[(5*R*,6*R*,7*S*,8*R*)-5,6,7,8-Tetrahydro-6,7,8-trihydroxy-5-(hydroxymethyl)imidazo[1,2-*a*]pyridin-2-yl]propanoic Acid (**12**). A soln. of **11** (15 mg, 52.4 μmol) in 1M aq. HCl (1 ml) was stirred at 60° for 1 h and applied to ion-exchange chromatography (*Amberlite CG-120*, H⁺ form, elution with 0.1M aq. NH₃). Evaporation, dissolving in H₂O (3 ml), and lyophilisation yielded **12** (12.2 mg, 85%) as a colourless hygroscopic resin. *R*_f (AcOEt/MeOH/H₂O 3:1:1) 0.14. [α]_D²⁵ = -11.5 (*c* = 0.26, MeOH). UV (MeOH): 225 (3.63). IR (KBr): 3600–2400s (br.), 2925s, 1944w, 1633m, 1568s, 1405s, 1309m, 1211m, 1166m, 1099s, 1071s, 1019m, 904m, 828m. ¹H-NMR (D₂O, 300 MHz): 2.51 (*t*, *J* = 7.2, 2 H), 2.88 (*t*, *J* = 7.2, 2 H) (CH₂CH₂); 4.03 (*dd*, *J* = 3.7, 12.5, CH–C(5)); 4.05 (*dd*, *J* = 4.1, 9.0, H–C(7)); 4.10 (*td*, *J* ≈ 3.1, 6.5, H–C(5)); 4.18 (*dd*, *J* = 2.8, 12.5, CH'–C(5)); 4.27 (*dd*, *J* = 6.5, 9.0, H–C(6)); 5.07 (*d*, *J* = 4.1, H–C(8)); 7.28 (*s*, H–C(3)). ¹³C-NMR (D₂O, 75 MHz): see Table 6; additionally, 21.80, 35.78 (2*t*, CH₂CH₂); 180.57 (*s*, C=O). HR-MALDI-MS: 295.0896 (98, C₁₁H₁₆N₂NaO₆, [*M* + *Na*]⁺; calc. 295.0906), 273.1075 (100, C₁₁H₁₇N₂O₆, [*M* + *H*]⁺; calc. 273.1086).

(5*R*,6*R*,7*S*,8*R*)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-(2-phenylethyl)imidazo[1,2-*a*]pyridine-6,7,8-triol (**10**). A soln. of **25** (50 mg, 75.4 μmol) in AcOEt/MeOH/H₂O 1:1:1 (1.5 ml) was treated with AcOH (1.5 ml) and 20% Pd(OH)₂/C (50 mg), hydrogenated at 6 bar for 120 h, and filtered through *Celite* (washing with MeOH/H₂O (9:1, 25 ml)). Evaporation of the combined filtrates, co-evaporation with toluene (3 × 5 ml), FC (AcOEt/MeOH/H₂O 15:1:1), FC (*RP-C18* SiO₂; MeOH/H₂O 7:3), and drying gave **10** (10.6 mg, ca. 46%) as a white solid containing substantial amounts of H₂O. The sample for microanalysis was dried for 4 d at 10⁻⁴ Torr. *R*_f (AcOEt/MeOH/H₂O 10:1:1) 0.17. [α]_D²⁵ = -19.4 (*c* = 0.98, MeOH). UV (MeOH): 211 (3.98). IR (KBr): 3600–2400s (br.), 3026m, 2925m, 2858m, 1938w, 1869w, 1801w, 1633w, 1604w, 1560w, 1497m, 1454m, 1401w, 1365w, 1331m, 1309m, 1263w, 1206w, 1182w, 1107s, 1060m, 1005m, 903m. ¹H-NMR (CD₃OD, 300 MHz): 2.77–2.82 (*m*, 2 H); 2.88–2.93 (*m*, 2 H) (CH₂CH₂); 3.77 (*dd*, *J* = 3.7, 9.3, H–C(7)); 3.78 (*ddd*, *J* = 2.5, 5.6, 7.5, H–C(5)); 3.87 (*dd*, *J* = 5.3, 11.8, CH–C(5)); 4.09 (*dd*, *J* = 7.8, 9.3, H–C(6)); 4.13 (*dd*, *J* = 2.5, 11.8, CH'–C(5)); 4.80 (*d*, *J* = 3.7, H–C(8)); 7.02 (*s*, H–C(3)); 7.10–7.27 (*m*, 5 arom. H). ¹³C-NMR (CD₃OD, 75 MHz): see Table 6; additionally, 31.29, 36.88 (2*t*); 126.73 (*d*, C(4) of Ph); 129.16 (2*d*); 129.24 (2*d*); 142.70, 142.98 (2*s*, C(1) of Ph, C(2)). HR-MALDI-MS: 327.1315 (13, C₁₆H₂₀N₂NaO₄, [*M* + *Na*]⁺; calc. 327.1321), 305.1491 (100, C₁₆H₂₁N₂O₄, [*M* + *H*]⁺; calc. 305.1501), 287.1387 (11, C₁₆H₁₉N₂O₃, [*M* – *OH*]⁺; calc. 287.1396). Anal. calc. for C₁₆H₂₀N₂O₄ · 0.5 H₂O (313.36): C 61.33, H 6.75, N 8.94; found: C 61.55, H 6.78, N 8.75.

(5*R*,6*R*,7*S*,8*R*)-5,6,7,8-Tetrahydro-6,7,8-tris(benzyloxy)-5-[(benzyloxy)methyl]-2-(2-phenylethynyl)imidazo[1,2-*a*]pyridine (**27**). At 23°, a suspension of **20** (305 mg, 0.444 mmol), Pd(PPh₃)₄ (25 mg, 21.6 μmol), CuI (9 mg, 47.3 μmol), and Et₃N (300 μl, 2.15 mmol) in degassed DMF (7.5 ml) was treated with phenylacetylene (150 μl, 1.37 mmol), stirred at 80° for 3 h, cooled to r.t., diluted with Et₂O (50 ml), and washed with sat. NH₄Cl soln. (3 × 20 ml). The combined aq. layers were extracted with Et₂O (3 × 15 ml). The combined org. layers were washed with H₂O (25 ml) and brine (25 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 1:0 → 7:1 → 4:1 → 1:2) gave **27** (245 mg, 83%) and **17** (24 mg, 10%). Oils.

Data of 27: *R*_f (hexane/AcOEt 4:1) 0.27. [α]_D²⁵ = -27.8 (*c* = 0.99, CHCl₃). UV (CHCl₃): 299 (4.2), 283 (4.2), 252 (4.0), 241 (4.0). IR (CHCl₃): 3157w, 3089w, 3066w, 2941m, 2868m, 2100w, 1952w, 1876w, 1811w, 1731w, 1599s, 1586m, 1496s, 1454s, 1364m, 1301m, 1174m, 1112s, 1050s, 1028s, 913w. ¹H-NMR (CDCl₃, 400 MHz): see Table 4; additionally, 4.46 (br. *s*, PhCH₂); 4.59 (*d*, *J* = 12.0, PhCH); 4.61 (*d*, *J* = 11.2, PhCH); 4.659 (*d*, *J* = 12.0, PhCH); 4.664 (*d*, *J* = 12.2, PhCH); 4.760 (*d*, *J* = 12.1, PhCH); 4.99 (*d*, *J* = 11.2, PhCH); 7.23–7.36 (*m*, 21 arom. H); 7.40–7.42 (*m*, 2 arom. H); 7.52–7.54 (*m*, H–C(2) and H–C(6) of Ph). ¹³C-NMR (CDCl₃, 100 MHz): see Table 5;

additionally, 70.68 (*t*, PhCH₂); 71.77 (*t*, PhCH₂); 73.20 (*t*, PhCH₂); 74.90 (*t*, PhCH₂); 82.98 (*s*, C≡C–C(2)); 89.31 (*s*, C≡C–C(2)); 123.23 (*s*, C(1) of Ph); 127.53–128.49 (several *d*); 131.48 (2*d*, C(2) and C(6) of Ph); 137.32, 137.66, 137.86, 137.93 (4*s*). HR-MALDI-MS: 683.2916 (26, C₄₄H₄₀N₂NaO₄, [M + Na]⁺; calc. 683.2886), 661.3069 (100, C₄₄H₄₁N₂O₄, [M + H]⁺; calc. 661.3066), 553.2499 (63, C₃₇H₃₃N₂O₃, [M – BnO]⁺; calc. 553.2491). Anal. calc. for C₄₄H₄₀N₂O₄ (660.81): C 79.98, H 6.10, N 4.24; found: C 79.91, H 6.11, N 4.09.

Hydrogenation of 27. A soln. of **27** (91 mg, 0.1377 mmol) in AcOEt/MeOH/H₂O 3 : 1 : 1 (2.5 ml) was treated with AcOH (2.5 ml), 20% Pd(OH)₂/C (90 mg), hydrogenated at 6 bar for 41 h, and filtered through *Celite* (washing with MeOH/H₂O (9 : 1, 25 ml)). Evaporation of combined filtrates, co-evaporation with toluene (3 × 5 ml), FC (AcOEt/MeOH/H₂O 15 : 1 : 1), and FC (RP-C18 SiO₂; MeOH/H₂O 7 : 3) afforded **10** (33.4 mg, 80%).

(5*R*,6*R*,7*S*,8*R*)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-(phenylethynyl)imidazo[1,2-*a*]pyridine-6,7,8-triol (**28**). A soln. of **27** (90 mg, 0.136 mmol) in CH₂Cl₂ (3.6 ml) was treated at –78° with 1*M* BCl₃ in CH₂Cl₂ (2.25 ml, 2.25 mmol), stirred until the mixture had reached a temp. of 10° (*ca.* 5 h), cooled to –78°, treated with H₂O (3 ml), neutralised with aq. NH₃ (1 ml), and evaporated. FC (AcOEt/MeOH/H₂O 1 : 0 : 0 → 20 : 1 : 1), lyophilisation, and drying afforded **28** (34.7 mg, *ca.* 85%) as a yellowish hygroscopic resin containing substantial amounts of H₂O. The sample for microanalysis was dried for 4 d at 10^{–4} Torr. R_f (AcOEt/MeOH/H₂O 10 : 1 : 1) 0.16. [α]_D²⁵ = –16.0 (*c* = 0.80, MeOH). UV (MeOH): 265 (4.02), 249 (4.02), 238 (4.05), 220 (4.12). IR (KBr): 3600–2400s (br.), 2925*m*, 2851*m*, 2219*w*, 2072*w*, 1958*w*, 1893*w*, 1721*w*, 1656*m*, 1630*m*, 1598*m*, 1550*m*, 1513*w*, 1487*m*, 1442*m*, 1406*m*, 1384*m*, 1314*m*, 1261*m*, 1210*m*, 1181*m*, 1094*s*, 1068*s*, 1008*m*, 902*m*, 841*w*, 805*w*. ¹H-NMR (CD₃OD, 300 MHz): 3.84 (*dd*, *J* = 3.7, 9.0, irradi. at 4.13 → *d*, *J* = 3.7, irradi. at 4.82 → *d*, *J* ≈ 8.7, H–C(7)); 3.87–3.93 (*m*, H–C(5)); 3.91 (*dd*, *J* = 5.9, 13.7, CH–C(5)); 4.13 (*dd*, *J* ≈ 6.9, 9.3, irradi. at 3.84 → *d*, *J* ≈ 5.0, H–C(6)); 4.17 (*dd*, *J* = 5.0, 14.0, CH–C(5)); 4.82 (*d*, *J* = 3.7, irradi. at 3.84 → *s*, H–C(8)); 7.31–7.38 (*m*, H–C(3), H–C(4), and H–C(5) of Ph); 7.43–7.49 (*m*, H–C(2) and H–C(6) of Ph); 7.60 (*s*, H–C(3)). ¹³C-NMR (CD₃OD, 75 MHz): see Table 6; additionally, 83.54 (*s*, C≡C–C(2)); 90.07 (*s*, C≡C–C(2)); 124.30, 124.70 (2*s*, C(1) of Ph, C(2)); 129.20 (*d*, C(4) of Ph); 129.37 (2*d*, C(3) and C(5) of Ph); 132.11 (2*d*, C(2) and C(6) of Ph). HR-MALDI-MS: 323.0995 (5, C₁₆H₁₆N₂NaO₄, [M + Na]⁺; calc. 323.1008); 301.1178 (100, C₁₆H₁₇N₂O₄, [M + H]⁺; calc. 301.1188); 283.1070 (8, C₁₆H₁₅N₂O₃, [M – OH]⁺; calc. 283.1083). Anal. calc. for C₁₆H₁₆N₂O₄ · 0.6 H₂O (311.12): C 61.77, H 5.57, N 9.00; found: C 61.73, H 5.54, N 8.90.

(5*R*,6*R*,7*S*,8*R*)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-[(*E*)-phenylethenyl]imidazo[1,2-*a*]pyridine-6,7,8-triol (**29**). *a*) A soln. of **25** (40 mg, 60.3 μmol) in CH₂Cl₂ (1.5 ml) was treated at –78° with 1*M* BCl₃ in CH₂Cl₂ (1.05 ml, 1.05 mmol), stirred until the mixture had reached a temp. of 15° (*ca.* 5 h), cooled to –78°, treated with H₂O (3 ml), neutralised with aq. NH₃ (1 ml), and evaporated. FC (AcOEt/MeOH/H₂O 1 : 0 : 0 → 15 : 1 : 1), lyophilisation, and drying yielded **29** (6.2 mg, *ca.* 34%) as a yellowish hygroscopic resin containing substantial amounts of AcOEt and H₂O. The sample for microanalysis was dried for 4 d at 10^{–4} Torr.

b) A soln. of **25** (30 mg, 45.3 μmol) in CH₂Cl₂ (1 ml) was treated with AlCl₃ (97 mg, 0.727 mmol) and *N,N*-dimethylaniline (70 μl, 0.552 mmol), stirred for 18 h at 22°, and treated with H₂O (15 ml). The mixture was diluted with AcOEt (15 ml) and extracted with H₂O. Evaporation of the aq. layer, FC (as described in *a*), lyophilisation, and drying yielded **29** (5.7 mg, *ca.* 42%) containing substantial amounts of AcOEt and H₂O.

Data of 29: R_f (AcOEt/MeOH/H₂O 10 : 1 : 1) 0.13. [α]_D²⁵ = +2.5 (*c* = 0.25, MeOH). UV (MeOH): 295 (4.19), 226 (4.04), 203 (4.22). IR (KBr): 3600–2400s (br.), 2925*m*, 2851*w*, 1633*w*, 1597*w*, 1535*w*, 1513*w*, 1490*w*, 1443*w*, 1381*w*, 1323*w*, 1261*w*, 1208*w*, 1180*w*, 1152*w*, 1095*m*, 1068*m*, 963*w*, 902*w*, 833*w*, 762*w*, 693*m*. ¹H-NMR (CD₃OD, 300 MHz): 3.83 (*dd*, *J* = 3.7, 9.3, H–C(7)); 3.85–3.91 (*m*, H–C(5)); 3.93 (*dd*, *J* = 5.6, 11.5, CH–C(5)); 4.13 (*dd*, *J* = 7.2, 9.3, H–C(6)); 4.19 (*dd*, *J* = 2.5, 11.5, CH–C(5)); 4.86 (*d*, *J* = 3.7, H–C(8)); 7.01 (*d*, *J* = 16.2, C(2)–CH=CH); 7.15 (*d*, *J* = 16.5, C(2)–CH=CH); 7.16–7.23 (*m*, H–C(4) of Ph); 7.27–7.34 (*m*, H–C(3) and H–C(5) of Ph); 7.44 (*s*, H–C(3)); 7.45–7.50 (*m*, H–C(2) and H–C(6) of Ph). ¹³C-NMR (CD₃OD, 75 MHz): see Table 6; additionally, 117.85 (*d*); 120.68 (*d*); 127.03 (*d*, C(2) and C(6) of Ph); 128.11 (*d*); 128.22 (*d*); 129.49 (*d*, C(3) and C(5) of Ph); 138.78 (*s*, C(1) of Ph). HR-MALDI-MS: 325.1160 (16, C₁₆H₁₈N₂NaO₄, [M + Na]⁺; calc. 325.1164); 303.1342 (100, C₁₆H₁₉N₂O₄, [M + H]⁺; calc. 303.1345); 285.1230 (16, C₁₆H₁₇N₂O₃, [M – OH]⁺; calc. 285.1239). Anal. calc. for C₁₆H₁₈N₂O₄ · 0.5 AcOEt · 0.5 H₂O (355.39): C 60.83, H 6.52, N 7.88; found: C 60.67, H 6.28, N 7.88.

(5*R*,6*R*,7*S*,8*R*)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-2-(chloromethyl)-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyridine (**30**). A soln. of **23** (85 mg, 0.144 mmol) in CH₂Cl₂ (3 ml) was treated with SOCl₂ (20 μl, 0.275 mmol), stirred at 23° for 40 min, and treated with sat. NaHCO₃ soln. (10 ml). The mixture was diluted with Et₂O (15 ml) and washed with sat. NaHCO₃ soln. (2 × 10 ml). The combined aq. layers were extracted with Et₂O (2 × 10 ml). The org. layers were combined, washed with H₂O (15 ml) and brine (15 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 3 : 1) gave **30** (76 mg, 86%). Colourless oil. R_f (hexane/AcOEt 3 : 1) 0.12. [α]_D²⁵ = –17.7 (*c* = 1.02, CHCl₃). UV (CHCl₃): 258 (3.04), 240 (3.57). IR (CHCl₃): 3067*w*, 3007*m*,

2868w, 1959w, 1879w, 1813w, 1497m, 1454m, 1363m, 1260m, 1097s, 1028s, 914w. ¹H-NMR (CDCl₃, 300 MHz): see Table 4; additionally, 4.44 (*d*, *J* = 12.5, PhCH); 4.48 (*d*, *J* = 12.5, PhCH); 4.55 (*d*, *J* = 12.1, PhCH); 4.58 (*s*, CH₂Cl); 4.61 (*d*, *J* ≈ 10.9, PhCH); 4.66 (*d*, *J* = 12.1, PhCH); 4.69 (*d*, *J* = 12.1, PhCH); 4.74 (*d*, *J* = 12.1, PhCH); 5.00 (*d*, *J* = 11.2, PhCH); 7.24–7.34 (*m*, 18 arom. H); 7.37–7.40 (*m*, 2 arom. H). ¹³C-NMR (CDCl₃, 75 MHz): see Table 5; additionally, 39.91 (*t*, CH₂–C(2)); 70.83, 70.86 (*2t*, PhCH₂, CH₂–C(5)); 71.91 (*t*, PhCH₂); 73.29 (*t*, PhCH₂); 75.05 (*t*, PhCH₂); 127.73–128.75 (several *d*); 137.67, 138.02, 138.18, 138.36, 138.80 (5s). HR-MALDI-MS: 1145.5028 (43), 631.2339 (18, C₃₇H₃₇ClN₂NaO₄, [M + Na]⁺; calc. 631.2339), 609.2519 (91, C₃₇H₃₈ClN₂O₄, [M + H]⁺; calc. 609.2520), 573.2754 (59, C₃₇H₃₇N₂O₄, [M – Cl]⁺; calc. 573.2753), 501.1963 (100, C₃₀H₃₀ClN₂O₃, [M – BnO]⁺; calc. 501.1945), 467.2372 (50). Anal. calc. for C₃₇H₃₇ClN₄ (609.16): C 72.95, H 6.12, N 4.60; found: C 73.04, H 6.42, N 4.33.

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2-(phenoxymethyl)imidazo[1,2-*a*]pyridine (**31**). *a*) A suspension of **30** (14.5 mg, 23.8 μmol), phenol (3.4 mg, 36.1 μmol), and K₂CO₃ (4.9 mg, 35.5 μmol) in THF (1 ml) was stirred for 13 h at 55–60°, diluted with Et₂O (15 ml), and washed with sat. NH₄Cl soln. (3 × 8 ml). The combined aq. layers were extracted with Et₂O (2 × 8 ml). The combined org. layers were washed with H₂O (10 ml) and brine (10 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 3:1) gave **31** (7.9 mg, 50%). Colourless oil.

b) A suspension of **30** (24 mg, 39.4 μmol), phenol (8 mg, 85.0 μmol), and *t*-BuOK (7.5 mg, 66.8 μmol) in DMF (1 ml) was stirred for 4 h at 80°. Workup and FC as described in *a* gave **31** (16.2 mg, 74%).

c) As described in *b*, but with K₂CO₃ instead of *t*-BuOK, yielding 60% of **31**.

d) A soln. of **30** (16 mg, 26.3 μmol) in DMF (1 ml) was treated with 0.26M soln. of NaOPh (141 μl, 36.7 μmol, prepared by the addition of Na (18 mg, 0.783 mmol) to a soln. of PhOH (76 mg, 0.808 mmol) in DMF (3 ml) at 23°) and stirred for 4 h at 80°. Workup and FC as described in *a* gave **31** (6.6 mg, 38%).

e) A soln. of **23** (100 mg, 0.169 mmol) in CH₂Cl₂ (4 ml) was treated with SOCl₂ (25 μl, 0.344 mmol), stirred at 23° for 3 h, and treated with sat. NaHCO₃ soln. (5 ml). The mixture was diluted with Et₂O (25 ml) and washed with sat. NaHCO₃ soln. (3 × 15 ml). The combined aq. layers were extracted with Et₂O (2 × 15 ml). The combined org. layers were washed with H₂O (25 ml) and brine (25 ml), dried (MgSO₄), and filtered. After evaporation, crude **30** (96 mg of a yellowish oil) was dissolved in DMF (4 ml), treated with *t*-BuOK (27 mg, 0.241 mmol) and PhOH (29 mg, 0.308 mmol), and stirred for 3.5 h at 80°. Workup and FC as described in *a* gave **31** (79.1 mg, 70% from **23**).

Data of **31**: R_f (hexane/AcOEt 2:1) 0.28. [α]_D²⁵ = –22.5 (*c* = 1.00, CHCl₃). UV (CHCl₃): 271 (3.3), 265 (3.2), 240 (3.4). IR (CHCl₃): 3157w, 3089w, 3066m, 2941m, 2868m, 1952w, 1876w, 1811w, 1731w, 1599m, 1586m, 1496s, 1454s, 1364m, 1301m, 1174m, 1112s, 1050s, 1028s, 913w. ¹H-NMR (CDCl₃, 400 MHz): see Table 7; additionally, 4.43 (br. s, PhCH₂); 4.60 (*d*, *J* = 11.2, PhCH); 4.61 (*d*, *J* = 12.1, PhCH); 4.67 (*d*, *J* = 12.0, 2 PhCH); 4.76 (*d*, *J* = 12.2, PhCH); 4.98 (*d*, *J* = 11.5, CH–C(2)); 4.99 (*d*, *J* = 11.1, PhCH); 5.02 (*d*, *J* = 11.7, CH'–C(2)); 6.94 (*tt*, *J* = 1.0, 7.3, H–C(4) of Ph); 6.99–7.02 (*m*, H–C(2) and H–C(6) of Ph); 7.23–7.34 (*m*, 18 arom. H, H–C(3) and H–C(5) of Ph, H–C(3)); 7.38–7.41 (*m*, 2 arom. H). ¹³C-NMR (CDCl₃, 100 MHz): see Table 5; additionally, 64.32 (*t*, CH₂–C(2)); 70.65 (*t*, PhCH₂); 71.77 (*t*, PhCH₂); 73.16 (*t*, PhCH₂); 74.92 (*t*, PhCH₂); 114.83 (*d*, C(2) and C(6) of Ph); 120.78 (*d*, C(4) of Ph); 127.46–128.48 (several *d*); 129.35 (*d*, C(3) and C(5) of Ph); 137.45, 137.79, 137.97 (3s), 138.17 (2s, including C(2)); 158.76 (*s*, C(1) of Ph). HR-MALDI-MS: 689.2968 (26, C₄₃H₄₂N₂O₅, [M + Na]⁺; calc. 689.2991), 667.3172 (100, C₄₃H₄₃N₂O₅, [M + H]⁺; calc. 667.3171), 573.2733 (18, C₃₇H₃₇N₂O₄, [M – PhO]⁺; calc. 573.2753), 559.2594 (21, C₃₆H₃₅N₂O₄, [M – BnO]⁺; calc. 559.2597), 465.2172 (11, C₃₀H₂₉N₂O₃, [M – BnO – PhOH]⁺; calc. 465.2178), 375.1705 (24), 359.1751 (14). Anal. calc. for C₄₃H₄₂N₂O₅ (666.82): C 77.45, H 6.35, N 4.20; found: C 77.39, H 6.50, N 4.18.

(5R,6R,7S,8R)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-(phenoxymethyl)imidazo[1,2-*a*]pyridine-6,7,8-triol (**32**) and (5R,6R,7S,8R)-2-[(Cyclohexyloxy)methyl]-5,6,7,8-tetrahydro-5-(hydroxymethyl)imidazo[1,2-*a*]pyridine-6,7,8-triol (**33**). A soln. of **31** (39 mg, 58.5 μmol) in AcOEt/MeOH/H₂O 3:1:1 (2 ml) was treated with AcOH (2 ml) and 20% Pd(OH)₂/C (40 mg), and hydrogenated at atmospheric pressure for 44 h. The suspension was filtered through *Celite*, and the residue was washed with MeOH/H₂O 9:1 (30 ml). Evaporation of the combined filtrates, co-evaporation with toluene (3 × 5 ml), FC (AcOEt/MeOH/H₂O 1:0:0 → 15:1:1 → 10:1:1), and drying afforded **32** (11.3 mg, ca. 63%) containing substantial amounts of H₂O, and **33** (1.7 mg, 9%). Colourless oils. The sample of **32** for microanalysis was dried for 4 d at 10^{–4} Torr.

Data of **32**: R_f (AcOEt/MeOH/H₂O 10:1:1) 0.20. [α]_D²⁵ = –18.8 (*c* = 0.64, MeOH). UV (MeOH): 277 (3.10), 271 (3.19), 219 (4.12). IR (KBr): 3600–2400s (br.), 2925m, 2857m, 1631w, 1599s, 1586m, 1496s, 1461m, 1384m, 1300m, 1239s, 1176m, 1094s, 1080s, 1030m, 1006m, 989m, 902m, 859m. ¹H-NMR (CD₃OD, 300 MHz): 3.81 (*dd*, *J* = 3.7, 9.3, irradi. at 4.83 → *d*, *J* = 9.3, H–C(7)); 3.83–3.94 (*m*, H–C(5), CH–C(5)); 4.07–4.21 (*m*, H–C(6), CH'–C(5)); 4.83 (*d*, *J* = 3.7, irradi. at 3.81 → *s*, H–C(8)); 4.95 (br. s, CH₂–C(2)); 6.91 (*tt*, *J* = 0.9,

Table 7. Selected $^1\text{H-NMR}$ Chemical Shifts [ppm] and Coupling Constants [Hz] of the Protected Imidazoles **31**, **34**, **36–39**, **44**, **45**, **48**, and **49** in CDCl_3

	31	34	36	37	38	39	44	45	48	49
H–C(3)	^{a)}	7.04	^{a)}	^{a)}	^{a)}	^{a)}	7.85	7.80	7.71	8.11
H–C(5)	4.10	4.07	4.12	4.13	4.10	4.14	4.16	4.12	4.14	4.29
H–C(6)	4.28	4.28	4.30	4.28	4.24	4.28	4.28	4.25	4.18	4.34
H–C(7)	3.88	3.87	3.88	3.90	3.87	3.90	3.86	3.82	3.84	4.07
H–C(8)	4.80	4.77	4.77	4.80	4.75	4.81	4.82	4.80	4.74	5.45
CH–C(5)	3.60	3.59	3.62	3.62	3.59	3.62	3.57	3.54	3.56	3.71
CH'–C(5)	3.74	3.73	3.76	3.76	3.73	3.76	3.72	3.69	3.69	3.79
$J(5,6)$	7.4	7.2	7.2	7.2	7.2	7.2	7.2	7.2	6.9	6.5
$J(6,7)$	9.4	9.3	9.3	9.3	9.0	9.3	9.3	9.3	8.4	8.4
$J(7,8)$	3.1	3.0	3.1	3.1	3.4	3.1	2.8	2.8	3.1	2.8
$J(5,\text{CH})$	7.0	6.8	6.8	7.2	7.2	7.2	7.2	7.2	7.5	6.5
$J(5,\text{CH}')$	3.0	3.1	3.1	2.8	3.1	3.1	3.1	3.1	2.5	3.4
$J(\text{CH},\text{CH}')$	10.1	10.1	10.0	10.0	10.0	10.0	10.0	10.0	10.3	10.0

^{a)} Hidden by signals of the Ph groups at 7.21–7.41 ppm.

7.2, H–C(4) of Ph); 6.94–6.99 (*m*, H–C(2) and H–C(6) of Ph); 7.21–7.28 (*m*, H–C(3) and H–C(5) of Ph); 7.43 (*s*, H–C(3)). $^{13}\text{C-NMR}$ (CD_3OD , 75 MHz): see Table 6; additionally, 64.55 (*t*, $\text{CH}_2\text{-C}(2)$); 115.61 (*d*, C(2) and C(6) of Ph); 121.71 (*d*, C(4) of Ph); 130.27 (*d*, C(3) and C(5) of Ph); 159.90 (*s*, C(1) of Ph). HR-MALDI-MS: 329.1109 (62, $\text{C}_{15}\text{H}_{18}\text{N}_2\text{NaO}_5$, $[\text{M} + \text{Na}]^+$; calc. 329.1113); 307.1290 (82, $\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}_5$, $[\text{M} + \text{H}]^+$; calc. 307.1294); 213.0867 (100, $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_4$, $[\text{M} - \text{PhO}]^+$; calc. 213.0875). Anal. calc. for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_5 \cdot 0.5 \text{H}_2\text{O}$ (315.33): C 57.14, H 6.07, N 8.88; found: C 57.14, H 5.98, N 8.64.

Data of **33**: R_f (AcOEt/MeOH/ H_2O 10:1:1) 0.11. $^1\text{H-NMR}$ (CD_3OD , 300 MHz): 1.20–1.38 (*m*, 3 CH_2 of C_6H_{11}); 1.70–1.80 (*m*, CH_2 of C_6H_{11}); 1.89–2.00 (*m*, CH_2 of C_6H_{11}); 3.36–3.48 (*m*, H–C(1) of C_6H_{11}); 3.79 (*dd*, $J = 3.7, 9.3$, H–C(7)); 3.85 (*ddd*, $J \approx 2.5, 5.6, 8.1$, H–C(5)); 3.89 (*dd*, $J = 5.6, 11.5$, CH–C(5)); 4.10 (*dd*, $J = 7.5, 9.3$, H–C(6)); 4.16 (*dd*, $J = 2.5, 11.5$, CH'–C(5)); 4.44 (*br. s*, $\text{CH}_2\text{-C}(2)$); 4.80 (*d*, $J = 3.7$, H–C(8)); 7.30 (*s*, H–C(3)). HR-MALDI-MS: 335.1576 (61, $\text{C}_{15}\text{H}_{24}\text{N}_2\text{NaO}_5$, $[\text{M} + \text{Na}]^+$; calc. 335.1583); 313.1754 (41, $\text{C}_{15}\text{H}_{25}\text{N}_2\text{O}_5$, $[\text{M} + \text{H}]^+$; calc. 313.1763); 213.0870 (100, $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_4$, $[\text{M} - \text{c-C}_6\text{H}_{11}\text{O}]^+$; calc. 213.0875).

BCl_3 -Promoted Debenzylation of **31**. *a)* A soln. of **31** (10 mg, 15.0 μmol) in CH_2Cl_2 (0.4 ml) was treated at -78° with 1M BCl_3 in CH_2Cl_2 (0.25 ml, 0.25 mmol), stirred until the mixture had reached a temp. of 15° (*ca.* 4.5 h), cooled to -78° , treated with H_2O (1 ml), and evaporated. The residue was taken up in H_2O (2 ml) and applied to ion-exchange chromatography (Amberlite CG-120, H^+ form, elution with 0.1M aq. NH_3). Evaporation and lyophilisation gave a 1:5 mixture of **35** and a product missing the PhO group (2.7 mg).

b) As described in *a*, but the mixture was neutralised with Amberlite IRA-68 after the addition of H_2O . Filtration, evaporation, and ion-exchange chromatography (Amberlite CG-120, H^+ form, elution with 0.1M aq. NH_3) gave a 1:1 mixture of **35** and a product missing the PhO group (3.1 mg).

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2-[(phenylamino)methyl]imidazo[1,2-a]pyridine (**34**). A suspension of **22** (50.0 mg, 84.9 μmol) and MgSO_4 (12 mg, 99.7 μmol) in CH_2Cl_2 (1 ml) was treated with freshly distilled PhNH_2 (9 μl , 98.7 μmol) and stirred for 4 h at 23° . The mixture was diluted with Et_2O (15 ml) and washed with sat. NaHCO_3 soln. (3×10 ml). The combined aq. layers were extracted with Et_2O (2×10 ml). The combined org. layers were washed with H_2O (15 ml) and brine (15 ml), dried (MgSO_4), filtered, and evaporated. The $^1\text{H-NMR}$ spectrum of the crude product (57 mg) showed a mixture of the corresponding imine and starting material in a ratio *ca.* 91:9. This mixture was diluted with EtOH (2 ml), treated with NaBH_4 (10 mg, 0.264 mmol), stirred for 3 h at 23° , treated with H_2O (0.3 ml), evaporated, diluted with Et_2O (20 ml), and washed with sat. NH_4Cl soln. (3×15 ml). The combined aq. layers were extracted with Et_2O (2×15 ml). The combined org. layers were washed with H_2O (25 ml) and brine (25 ml), dried (MgSO_4), filtered, and evaporated. FC (hexane/AcOEt 2:1 \rightarrow 1:1 \rightarrow 1:2) gave **34** (42.6 mg, 75%) and **23** (1.8 mg, 4%). Oils.

Data of **34**: R_f (hexane/AcOEt 1:1) 0.19. $[\alpha]_D^{25} = -27.1$ ($c = 1.00$, CHCl_3). UV (CHCl_3): 295 (3.3), 244 (4.1). IR (CHCl_3): 3416w, 3089w, 3065w, 3032w, 2938m, 2868m, 1952w, 1876w, 1812w, 1731w, 1603s, 1504s, 1454s,

1430w, 1364m, 1311m, 1260m, 1180w, 1099s, 1028s, 913w. ¹H-NMR (CDCl₃, 400 MHz): see Table 7; additionally, 4.11–4.19 (br. s, NH); 4.23 (br. s, CH₂–C(2)); 4.42 (br. s, PhCH₂); 4.60 (*d*, *J* = 11.2, PhCH); 4.62 (*d*, *J* = 12.0, PhCH); 4.68 (br. *d*, *J* ≈ 10.9, 2 PhCH); 4.76 (*d*, *J* = 11.3, PhCH); 4.98 (*d*, *J* = 11.2, PhCH); 6.65–6.72 (*m*, H–C(2), H–C(4), and H–C(6) of Ph); 7.14–7.19 (*m*, H–C(3) and H–C(5) of Ph); 7.21–7.34 (*m*, 18 arom. H); 7.36–7.39 (*m*, 2 arom. H). ¹³C-NMR (CDCl₃, 100 MHz): see Table 5; additionally, 42.29 (*t*, CH₂–C(2)); 70.77 (*t*, PhCH₂, CH₂–C(5)); 71.80 (*t*, PhCH₂); 73.21 (*t*, PhCH₂); 74.88 (*t*, PhCH₂); 113.15 (*d*, C(2) and C(6) of Ph); 117.50 (*d*, C(4) of Ph); 127.46–128.48 (several *d*); 129.13 (*d*, C(3) and C(5) of Ph); 137.52, 137.85, 138.03, 138.28 (4s); 148.26 (*s*, C(1) of Ph). HR-MALDI-MS: 704.2906 (1, C₄₃H₄₃KN₃O₄, [*M* + K]⁺; calc. 704.2890), 688.3140 (24, C₄₃H₄₃N₃NaO₄, [*M* + Na]⁺; calc. 688.3151), 666.3329 (24, C₄₃H₄₄N₃O₄, [*M* + H]⁺; calc. 666.3332), 573.2739 (100, C₃₇H₃₇N₂O₄, [*M* – PhNH]⁺; calc. 573.2753), 558.2759 (2, C₃₆H₃₆N₃O₃, [*M* – BnO]⁺; calc. 558.2756), 467.2322 (16). Anal. calc. for C₄₃H₄₃N₃O₄ (665.83): C 77.57, H 6.51, N 6.31; found: C 77.69, H 6.47, N 6.19.

(5R,6R,7S,8R)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-[(phenylamino)methyl]imidazo[1,2-*a*]pyridine-6,7,8-triol (**35**). A soln. of **34** (64 mg, 96.1 μmol) in CH₂Cl₂ (4.9 ml) was treated at –78° with 1M BCl₃ in CH₂Cl₂ (1.2 ml, 1.20 mmol), stirred until the mixture had reached a temp. of 15° (ca. 4.5 h), cooled to –78°, treated with H₂O (2 ml), and evaporated. The residue was taken up in H₂O (2 ml) and applied to ion-exchange chromatography (Amberlite CG-120, H⁺ form, elution with 0.1M aq. NH₃). Evaporation, lyophilisation, and drying gave **35** (22.6 mg, ca. 77%) as a colourless hygroscopic resin containing substantial amounts of H₂O. The sample for microanalysis was dried for 4 d at 10^{–4} Torr. R_f (AcOEt/MeOH/H₂O 10:1:1) 0.18. [α]_D²⁵ = –23.3 (*c* = 0.96, MeOH). UV (MeOH): 294 (3.28), 242 (4.02), 210 (4.02). IR (KBr): 3600–2400s (br.), 3053m, 2925m, 2852m, 1603s, 1506s, 1463m, 1432m, 1382w, 1312m, 1253m, 1180m, 1096s, 1066m, 1007w, 902w, 752m, 694m. ¹H-NMR (D₂O, 300 MHz): 3.80 (br. *td*, *J* ≈ 2.8, 8.7, irradi. at 3.96 → change, irradi. at 4.15 → change, H–C(5)); 3.84 (*dd*, *J* = 3.7, 10.0, irradi. at 4.15 → change, irradi. at 4.83 → *d*, *J* = 10.3, H–C(7)); 3.96 (*dd*, *J* = 3.4, 12.8, CH–C(5)); 4.12 (*dd*, *J* ≈ 2.5, 13.1, irradi. at 3.96 → change, CH–C(5)); 4.15 (*dd*, *J* = 8.7, 10.3, irradi. at 3.84 → change, H–C(6)); 4.17 (*d*, *J* = 15.9, CH–C(2)); 4.23 (*d*, *J* = 15.9, CH–C(2)); 4.83 (*d*, *J* = 3.7, irradi. at 3.84 → *s*, H–C(8)); 6.77–6.82 (*m*, H–C(2), H–C(4), and H–C(6) of Ph); 7.12 (*s*, H–C(3)); 7.18–7.23 (*m*, H–C(3) and H–C(5) of Ph). ¹³C-NMR (D₂O, 75 MHz): see Table 6; additionally, 41.22 (*t*, CH₂–C(2)); 114.80 (*d*, C(2) and C(6) of Ph); 119.03 (*d*, C(4) of Ph); 129.23 (*d*, C(3) and C(5) of Ph); 144.62 (*s*, C(1) of Ph). HR-MALDI-MS: 328.1271 (56, C₁₅H₁₉N₃NaO₄, [*M* + Na]⁺; calc. 328.1273), 306.1449 (100, C₁₅H₂₀N₃O₄, [*M* + H]⁺; calc. 306.1454), 213.0866 (49, C₉H₁₃N₂O₄, [*M* – PhNH]⁺; calc. 213.0875). Anal. calc. for C₁₅H₁₉N₃O₄ · 0.5 H₂O (314.34): C 57.32, H 6.41, N 13.37; found: C 57.10, H 6.31, N 13.03.

(5R,6R,7S,8R)-5,6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2-[(2-nitrophenoxy)methyl]imidazo[1,2-*a*]pyridine (**36**). A suspension of **23** (42 mg, 71.1 μmol) and NaH (8 mg, 0.183 mmol) in degassed DMF (1 ml) was treated with 1-fluoro-2-nitrobenzene (16 μl, 0.151 mmol), stirred for 1 h at 80°, cooled to r.t., diluted with Et₂O (20 ml), and washed with sat. NH₄Cl soln. (3 × 10 ml). The combined aq. layers were extracted with Et₂O (2 × 15 ml). The combined org. layers were washed with H₂O (30 ml) and brine (30 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 1:0 → 2:1 → 1:1) gave **36** (47.7 mg, 94%). Yellow oil. R_f (hexane/AcOEt 1:1) 0.26. [α]_D²⁵ = –33.1 (*c* = 1.00, CHCl₃). UV (CHCl₃): 326 (3.4), 259 (3.7), 240 (3.8). IR (CHCl₃): 3089w, 3067w, 2960m, 2869m, 1952w, 1890w, 1811w, 1731m, 1608s, 1584m, 1526s, 1496m, 1454s, 1356s, 1309m, 1276s, 1254s, 1166m, 1093s, 1047s, 1028s, 913w. ¹H-NMR (CDCl₃, 300 MHz): see Table 7; additionally, 4.45 (br. s, PhCH₂); 4.608 (*d*, *J* = 11.2, PhCH); 4.614 (*d*, *J* = 11.8, PhCH); 4.65 (*d*, *J* = 11.8, PhCH); 4.69 (*d*, *J* = 11.8, PhCH); 4.75 (*d*, *J* = 12.5, PhCH); 4.99 (*d*, *J* = 11.2, PhCH); 5.19 (br. s, CH₂–C(2)); 7.01 (*ddd*, *J* = 1.2, 7.5, 8.1, irradi. at 7.50 → br. *dd*, *J* ≈ 1.9, 7.8, irradi. at 7.83 → br. *dd*, *J* ≈ 0.9, 7.8, H–C(4) of C₆H₄NO₂); 7.22–7.41 (*m*, 20 arom. H, H–C(3), H–C(6) of C₆H₄NO₂); 7.50 (*ddd*, *J* = 1.9, 7.5, 9.3, irradi. at 7.01 → br. *dd*, *J* ≈ 2.8, 8.7, irradi. at 7.83 → br. *dd*, *J* ≈ 6.9, 8.4, H–C(5) of C₆H₄NO₂); 7.83 (*dd*, *J* = 1.9, 8.1, irradi. at 7.01 → br. *d*, *J* ≈ 2.5, irradi. at 7.50 → br. *d*, *J* ≈ 7.5, H–C(3) of C₆H₄NO₂). ¹³C-NMR (CDCl₃, 75 MHz): see Table 5; additionally, 66.42 (*t*, CH₂–C(2)); 70.53, 70.59 (2*t*, PhCH₂, CH₂–C(5)); 71.81 (*t*, PhCH₂); 73.21 (*t*, PhCH₂); 74.86 (*t*, PhCH₂); 115.65 (*d*, C(6) of C₆H₄NO₂); 120.42 (*d*, C(4) of C₆H₄NO₂); 125.46 (*d*, C(3) of C₆H₄NO₂); 127.43–128.38 (several *d*); 133.87 (*d*, C(5) of C₆H₄NO₂); 137.01, 137.30, 137.65, 137.81, 137.93 (5*s* including C(2)); 140.10 (*s*, C(2) of C₆H₄NO₂); 142.76 (*s*, C(8a)); 152.01 (*s*, C(1) of C₆H₄NO₂). HR-MALDI-MS: 734.2771 (18, C₄₃H₄₁N₃NaO₇, [*M* + Na]⁺; calc. 734.2842), 718.2896 (17, C₄₃H₄₁N₃NaO₆, [*M* + Na – O]⁺; calc. 718.2893), 712.3025 (43, C₄₃H₄₂N₃O₇, [*M* + H]⁺; calc. 712.3023), 702.2916 (10, C₄₃H₄₁N₃NaO₅, [*M* + Na – O₂]⁺; calc. 702.2944), 604.2491 (10, C₃₆H₃₄N₃O₆, [*M* – BnO]⁺; calc. 604.2447), 573.2767 (100, C₃₇H₃₇N₂O₄, [*M* – C₆H₄NO₂]⁺; calc. 573.2753), 467.2384 (42), 465.2240 (10, C₃₀H₂₉N₂O₃, [*M* – C₆H₄NO₂ – BnOH]⁺; calc. 465.2178), 359.1824 (16). Anal. calc. for C₄₃H₄₁N₃O₇ (711.81): C 72.56, H 5.81, N 5.90; found: C 72.29, H 6.00, N 5.98.

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2-[4-nitrophenoxy)methyl]imidazo[1,2-a]pyridine (**37**). A susp. of **23** (92 mg, 0.156 mmol) and NaH (15 mg, 0.344 mmol) in degassed DMF (3 ml) was treated with 1-fluoro-4-nitrobenzene (35 μ l, 0.330 mmol), stirred for 1 h at 80°, cooled to r.t., diluted with Et₂O (20 ml), and washed with sat. NH₄Cl soln. (3 \times 10 ml). The combined aq. layers were extracted with Et₂O (2 \times 15 ml). The combined org. layers were washed with H₂O (30 ml) and brine (30 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 1:0 \rightarrow 2:1 \rightarrow 1:1) gave **37** (99 mg, 89%). Yellow oil. *R_f* (hexane/AcOEt 1:1) 0.30. [α]_D²⁵ = -13.8 (*c* = 1.00, CHCl₃). UV (CHCl₃): 312 (4.1), 240 (3.7). IR (CHCl₃): 3089w, 3066w, 2938w, 2870w, 1953w, 1890w, 1812w, 1731m, 1608m, 1593s, 1515s, 1497s, 1454m, 1374m, 1343s, 1298m, 1254s, 1174m, 1112s, 1046m, 1028m, 990m, 914w. ¹H-NMR (CDCl₃, 300 MHz): see Table 7; additionally, 4.44 (*d*, *J* = 12.1, PhCH); 4.48 (*d*, *J* = 12.8, PhCH); 4.62 (*d*, *J* = 11.2, PhCH); 4.63 (*d*, *J* = 11.8, PhCH); 4.68 (*d*, *J* = 12.1, PhCH); 4.70 (*d*, *J* = 12.1, PhCH); 4.78 (*d*, *J* = 12.8, PhCH); 5.01 (*d*, *J* = 11.2, PhCH); 5.07 (*d*, *J* = 11.5, CH-C(2)); 5.07 (*d*, *J* = 11.5, CH'-C(2)); 7.05–7.12 (*m*, *J*_{vic} = 9.3, irradi. at 8.19 \rightarrow *s*, H-C(2) and H-C(6) of C₆H₄NO₂); 7.24–7.40 (*m*, 20 arom. H, H-C(3)); 8.16–8.22 (*m*, *J*_{vic} = 9.3, irradi. at 7.09 \rightarrow *s*, H-C(3) and H-C(5) of C₆H₄NO₂). ¹³C-NMR (CDCl₃, 75 MHz): see Table 5; additionally, 65.18 (*t*, CH₂-C(2)); 70.99 (*t*, PhCH₂, CH₂-C(5)); 72.05 (*t*, PhCH₂); 73.37 (*t*, PhCH₂); 75.13 (*t*, PhCH₂); 115.06 (*d*, C(2) and C(6) of C₆H₄NO₂); 126.02 (*d*, C(3) and C(5) of C₆H₄NO₂); 127.77–128.70 (several *d*); 137.58, 137.91, 138.04, 138.21 (4s); 141.72 (*s*, C(4) of C₆H₄NO₂); 163.96 (*s*, C(1) of C₆H₄NO₂). HR-MALDI-MS: 734.2789 (50, C₄₃H₄₁N₃NaO₇, [M + Na]⁺; calc. 734.2842), 718.2898 (66, C₄₃H₄₁N₃NaO₆, [M + Na - O]⁺; calc. 718.2893), 712.3026 (52, C₄₃H₄₂N₃O₇, [M + H]⁺; calc. 712.3023), 698.3189 (55, C₄₃H₄₄N₃O₆, [M + H - O₂ + H₂O]⁺; calc. 698.3230), 696.3040 (55, C₄₃H₄₂N₃O₆, [M + H - O]⁺; calc. 696.3073), 604.2490 (57, C₃₆H₃₄N₃O₆, [M - BnO]⁺; calc. 604.2447), 596.2674 (30), 588.2529 (31, C₃₆H₃₄N₃O₅, [M - O - BnO]⁺; calc. 588.2498), 574.2835 (100, C₃₇H₃₈N₂O₄, [M + H - C₆H₄NO₂]⁺; calc. 574.2831), 573.2774 (78, C₃₇H₃₇N₂O₄, [M - C₆H₄NO₂]⁺; calc. 573.2753), 467.2386 (48), 465.2244 (41, C₃₀H₂₉N₂O₃, [M - C₆H₄NO₂ - BnOH]⁺; calc. 465.2178), 375.1776 (74), 359.1827 (43). Anal. calc. for C₄₃H₄₁N₃O₇ (711.80): C 72.56, H 5.81, N 5.90; found: C 72.43, H 5.63, N 5.83.

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-2-[(2,4-dinitrophenoxy)methyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (**38**). A suspension of **23** (50 mg, 84.6 μ mol) and NaH (8 mg, 0.183 mmol) in degassed DMF (2 ml) was treated with 1-fluoro-2,4-dinitrobenzene (22 μ l, 0.180 mmol) and stirred for 5 h at 80°. No reaction was observed at this moment (TLC). The mixture was left to stand at 23° for 3 weeks, diluted with Et₂O (20 ml), and washed with sat. NH₄Cl soln. (3 \times 10 ml). The combined aq. layers were extracted with Et₂O (2 \times 15 ml). The combined org. layers were washed with H₂O (30 ml) and brine (30 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 1:0 \rightarrow 2:1 \rightarrow 1:1) gave **38** (40.0 mg, 63%) and **23** (2.8 mg, 6%) as yellow oils.

Data of **38**: *R_f* (hexane/AcOEt 1:1) 0.23. [α]_D²⁵ = -19.0 (*c* = 1.00, CHCl₃). UV (CHCl₃): 296 (4.0), 258 (3.9), 240 (3.9). IR (CHCl₃): 3090w, 3067w, 2961w, 2870m, 1952w, 1872w, 1810w, 1731s, 1608s, 1538s, 1496m, 1454m, 1420w, 1345s, 1314m, 1274s, 1152m, 1098s, 1071s, 1046s, 1028m, 970m, 914w. ¹H-NMR (CDCl₃, 300 MHz): see Table 7; additionally, 4.43 (br. *s*, PhCH₂); 4.59 (*d*, *J* = 11.2, PhCH); 4.60 (*d*, *J* = 12.1, PhCH); 4.65 (*d*, *J* = 12.5, PhCH); 4.67 (*d*, *J* = 11.8, PhCH); 4.74 (*d*, *J* = 12.1, PhCH); 4.96 (*d*, *J* = 11.2, PhCH); 5.29 (br. *s*, CH₂-C(2)); 7.21–7.36 (*m*, 20 arom. H, H-C(3)); 7.62 (*d*, *J* = 9.3, irradi. at 8.33 \rightarrow *s*, H-C(6) of C₆H₃N₂O₄); 8.33 (*dd*, *J* = 2.8, 9.3, irradi. at 7.62 \rightarrow br. *d*, *J* \approx 2.5, irradi. at 8.68 \rightarrow *d*, *J* = 9.3, H-C(5) of C₆H₃N₂O₄); 8.68 (*d*, *J* = 2.8, irradi. at 8.33 \rightarrow *s*, H-C(3) of C₆H₃N₂O₄). ¹³C-NMR (CDCl₃, 75 MHz): see Table 5; additionally, 66.86 (*t*, CH₂-C(2)); 70.54, 70.73 (2*t*, CH₂-C(5), PhCH₂); 71.88 (*t*, PhCH₂); 73.18 (*t*, PhCH₂); 74.80 (*t*, PhCH₂); 115.81 (*d*, C(6) of C₆H₃N₂O₄); 121.69 (*d*, C(3) of C₆H₃N₂O₄); 127.65–128.48 (several *d*); 128.71 (*d*, C(5) of C₆H₃N₂O₄); 137.26, 137.64, 137.73, 137.84 (4s); 139.06, 139.97 (2*s*, C(2) and C(4) of C₆H₃N₂O₄); 156.58 (*s*, C(1) of C₆H₃N₂O₄). HR-MALDI-MS: 779.2660 (1, C₄₃H₄₀N₄NaO₉, [M + Na]⁺; calc. 779.2693), 757.2862 (12, C₄₃H₄₁N₄O₉, [M + H]⁺; calc. 757.2873), 743.3071 (17), 741.2910 (13, C₄₃H₄₁N₄O₈, [M + H - O]⁺; calc. 741.2924), 649.2294 (8, C₃₆H₃₃N₄O₈, [M - BnO]⁺; calc. 649.2298), 573.2732 (100, C₃₇H₃₇N₂O₄, [M - C₆H₃N₂O₄]⁺; calc. 573.2732), 467.232 (28), 465.2167 (9, C₃₀H₂₉N₂O₃, [M - C₆H₃N₂O₄ - BnOH]⁺; calc. 465.2167), 359.1751 (12). Anal. calc. for C₄₃H₄₀N₄O₉ (756.81): C 68.24, H 5.33, N 7.40; found: C 68.25, H 5.45, N 7.27.

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2-[3-nitrophenoxy)methyl]imidazo[1,2-a]pyridine (**39**). A suspension of **23** (33 mg, 55.9 μ mol) and NaH (7 mg, 0.160 mmol) in degassed DMF (1 ml) was treated with 1-fluoro-3-nitrobenzene (12 μ l, 0.112 mmol), stirred for 1 h at 80° (no reaction) and then for 20 h at 140°, cooled to r.t., diluted with Et₂O (20 ml), and washed with sat. NH₄Cl soln. (3 \times 10 ml). The combined aq. layers were extracted with Et₂O (2 \times 15 ml). The combined org. layers were washed with H₂O (30 ml) and brine (30 ml), dried (MgSO₄), filtered, and evaporated. FC (hexane/AcOEt 1:0 \rightarrow 2:1 \rightarrow 1:1 \rightarrow 0:1) gave **39** (22.2 mg, 56%) and **23** (8.8 mg, 27%). Yellow oils.

Data of 39: R_f (hexane/AcOEt 1:1) 0.43. $[\alpha]_D^{25} = -16.6$ ($c = 0.89$, CHCl_3). UV (CHCl_3): 328 (3.3), 269 (3.8), 240 (3.9). IR (CHCl_3): 3089w, 3067w, 2932w, 2869w, 1951w, 1870w, 1811w, 1731w, 1619w, 1582w, 1530s, 1497m, 1482w, 1454m, 1352s, 1319m, 1284m, 1097s, 1027m, 990w, 912w. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): see Table 7; additionally, 4.47 (br. s, PhCH_2); 4.62 (*d*, $J = 11.5$, 2 PhCH); 4.688 (*d*, $J = 12.1$, PhCH); 4.693 (*d*, $J = 11.8$, PhCH); 4.77 (*d*, $J = 12.1$, PhCH); 5.01 (*d*, $J = 11.2$, PhCH); 5.05 (*d*, $J = 11.8$, $\text{CH}-\text{C}(2)$); 5.10 (*d*, $J = 11.8$, $\text{CH}'-\text{C}(2)$); 7.25–7.36 (*m*, 18 arom. H, $\text{H}-\text{C}(3)$, $\text{H}-\text{C}(6)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.37–7.42 (*m*, 2 arom. H); 7.42 (*t*, $J = 8.1$, $\text{H}-\text{C}(5)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.83 (*ddd*, $J = 0.9$, 2.2, 8.1, $\text{H}-\text{C}(4)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.91 (*t*, $J = 2.2$, $\text{H}-\text{C}(2)$ of $\text{C}_6\text{H}_4\text{NO}_2$). $^{13}\text{C-NMR}$ (CDCl_3 , 75 MHz): see Table 5; additionally, 64.89 (*t*, $\text{CH}_2-\text{C}(2)$); 70.73, 70.81 (2*t*, PhCH_2 , $\text{CH}_2-\text{C}(5)$); 71.81 (*t*, PhCH_2); 73.18 (*t*, PhCH_2); 74.94 (*t*, PhCH_2); 109.23 (*d*, $\text{C}(2)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 115.76 (*d*, $\text{C}(4)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 121.92 (*d*, $\text{C}(6)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 127.43–128.40 (several *d*); 129.71 (*d*, $\text{C}(5)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 137.27, 137.60, 137.75, 137.93 (4*s*); 148.97 (*s*, $\text{C}(3)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 159.07 (*s*, $\text{C}(1)$ of $\text{C}_6\text{H}_4\text{NO}_2$). HR-MALDI-MS: 734.2799 (73, $\text{C}_{43}\text{H}_{41}\text{N}_3\text{NaO}_7$, $[\text{M} + \text{Na}]^+$; calc. 734.2842), 718.290 (92, $\text{C}_{43}\text{H}_{41}\text{N}_3\text{NaO}_6$, $[\text{M} + \text{Na} - \text{O}]^+$; calc. 718.2893), 712.3022 (71, $\text{C}_{43}\text{H}_{42}\text{N}_3\text{O}_7$, $[\text{M} + \text{H}]^+$; calc. 712.3023), 698.3188 (100, $\text{C}_{43}\text{H}_{44}\text{N}_3\text{O}_6$, $[\text{M} + \text{H} - \text{O}_2 + \text{H}_2\text{O}]^+$; calc. 698.3230), 696.3047 (87, $\text{C}_{43}\text{H}_{42}\text{N}_3\text{O}_6$, $[\text{M} + \text{H} - \text{O}]^+$; calc. 696.3073), 604.2490 (98, $\text{C}_{36}\text{H}_{34}\text{N}_3\text{O}_6$, $[\text{M} - \text{BnO}]^+$; calc. 604.2447), 588.2529 (89, $\text{C}_{36}\text{H}_{34}\text{N}_3\text{O}_5$, $[\text{M} - \text{O} - \text{BnO}]^+$; calc. 588.2498), 573.2782 (81, $\text{C}_{37}\text{H}_{37}\text{N}_2\text{O}_4$, $[\text{M} - \text{C}_6\text{H}_4\text{NO}_3]^+$; calc. 573.2753), 465.2247 (63, $\text{C}_{30}\text{H}_{29}\text{N}_2\text{O}_3$, $[\text{M} - \text{C}_6\text{H}_4\text{NO}_3 - \text{BnOH}]^+$; calc. 465.2178), 375.1777 (70), 359.1828 (61). Anal. calc. for $\text{C}_{43}\text{H}_{41}\text{N}_3\text{O}_7$ (711.81): C 72.56, H 5.81, N 5.90; found: C 72.59, H 5.90, N 5.83.

(5*R*,6*R*,7*S*,8*R*)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-[(2-nitrophenoxy)methyl]imidazo[1,2-*a*]pyridine-6,7,8-triol (**40**). A soln. of **36** (16.5 mg, 23.2 μmol) in CH_2Cl_2 (1 ml) was treated with AlCl_3 (38 mg, 0.285 mmol) and anisole (41 μl , 0.375 mmol), stirred for 13 h at 22°, and treated with H_2O (15 ml). The mixture was diluted with AcOEt (15 ml). After extraction with H_2O , the aq. layer was evaporated. FC (AcOEt/MeOH/ H_2O 1:0:0 \rightarrow 15:1:1 \rightarrow 10:1:1) yielded **40** (6.1 mg, 75%). White solid. R_f (AcOEt/MeOH/ H_2O 15:1:1) 0.10. $[\alpha]_D^{25} = -17.8$ ($c = 0.30$, MeOH). UV (MeOH): 320 (3.22), 254 (3.27), 214 (4.23). IR (KBr): 3600–2400s (br.), 2924w, 2857w, 1630m, 1608s, 1584m, 1525s, 1487w, 1459m, 1446m, 1398w, 1381w, 1352m, 1286m, 1260m, 1177w, 1165m, 1149w, 1121m, 1087m, 1040m, 910w, 861w. $^1\text{H-NMR}$ (CD_3OD , 300 MHz): 3.81 (*dd*, $J = 3.7$, 9.3, $\text{H}-\text{C}(7)$); 3.84–3.94 (*m*, $\text{H}-\text{C}(5)$, $\text{CH}-\text{C}(5)$); 4.06–4.20 (*m*, $\text{H}-\text{C}(6)$, $\text{CH}'-\text{C}(5)$); 4.82 (*d*, $J = 3.7$, $\text{H}-\text{C}(8)$); 5.12 (br. s, $\text{CH}_2-\text{C}(2)$); 7.06 (*ddd*, $J = 1.2$, 7.5, 8.1, $\text{H}-\text{C}(4)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.41 (*dd*, $J = 1.2$, 8.4, $\text{H}-\text{C}(6)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.48 (*s*, $\text{H}-\text{C}(3)$); 7.57 (*ddd*, $J = 1.9$, 7.5, 8.4, $\text{H}-\text{C}(5)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.75 (*dd*, $J = 1.9$, 8.1, $\text{H}-\text{C}(3)$ of $\text{C}_6\text{H}_4\text{NO}_2$). $^1\text{H-NMR}$ ($\text{CD}_3\text{OD}/\text{D}_2\text{O}$ 4:1, 300 MHz): 3.87 (*dd*, $J = 3.7$, 10.0, $\text{H}-\text{C}(7)$); 3.89 (*ddd*, $J = 2.5$, 4.7, 7.8, $\text{H}-\text{C}(5)$); 3.96 (*dd*, $J = 4.7$, 11.8, $\text{CH}-\text{C}(5)$); 4.17 (*dd*, $J = 7.8$, 9.7, $\text{H}-\text{C}(6)$); 4.19 (*dd*, $J = 2.5$, 12.1, $\text{CH}'-\text{C}(5)$); 4.87 (*d*, $J = 3.7$, $\text{H}-\text{C}(8)$); 5.16 (br. s, $\text{CH}_2-\text{C}(2)$); 7.12 (*ddd*, $J = 1.2$, 7.2, 8.4, $\text{H}-\text{C}(4)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.42 (*dd*, $J = 0.9$, 8.7, $\text{H}-\text{C}(6)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.44 (*s*, $\text{H}-\text{C}(3)$); 7.65 (*ddd*, $J = 1.6$, 7.5, 8.7, $\text{H}-\text{C}(5)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.83 (*dd*, $J = 1.6$, 8.1, $\text{H}-\text{C}(3)$ of $\text{C}_6\text{H}_4\text{NO}_2$). $^{13}\text{C-NMR}$ (CD_3OD , 75 MHz): see Table 6; additionally, 66.57 (*t*, $\text{CH}_2-\text{C}(2)$); 116.52 (*d*, $\text{C}(6)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 122.32, 122.69 (2*d*, $\text{C}(4)$ of $\text{C}_6\text{H}_4\text{NO}_2$, $\text{C}(3)$); 126.21 (*d*, $\text{C}(3)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 135.27 (*d*, $\text{C}(5)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 141.75 (*s*, $\text{C}(2)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 151.66 (*s*, $\text{C}(1)$ of $\text{C}_6\text{H}_4\text{NO}_2$). HR-MALDI-MS: 374.0959 (100, $\text{C}_{15}\text{H}_{17}\text{N}_3\text{NaO}_7$, $[\text{M} + \text{Na}]^+$; calc. 374.0964), 360.1166 (54, $\text{C}_{15}\text{H}_{19}\text{N}_3\text{NaO}_6$, $[\text{M} + \text{Na} - \text{O}_2 + \text{H}_2\text{O}]^+$; calc. 360.1171), 358.1012 (85, $\text{C}_{15}\text{H}_{17}\text{N}_3\text{NaO}_6$, $[\text{M} + \text{Na} - \text{O}]^+$; calc. 358.1015), 352.1137 (46, $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}_7$, $[\text{M} + \text{H}]^+$; calc. 352.1145), 342.1061 (31, $\text{C}_{15}\text{H}_{17}\text{N}_3\text{NaO}_5$, $[\text{M} + \text{Na} - \text{O}_2]^+$; calc. 342.1066), 336.1186 (30, $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}_6$, $[\text{M} + \text{H} - \text{O}]^+$; calc. 336.1195), 320.1238 (83, $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}_5$, $[\text{M} + \text{H} - \text{O}_2]^+$; calc. 320.1246), 213.0868 (88, $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_4$, $[\text{M} - \text{C}_6\text{H}_4\text{NO}_3]^+$; calc. 213.0875).

(5*R*,6*R*,7*S*,8*R*)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-[(4-nitrophenoxy)methyl]imidazo[1,2-*a*]pyridine-6,7,8-triol (**41**). *a*) A soln. of **37** (16.7 mg, 23.5 μmol) in CH_2Cl_2 (1 ml) was treated with AlCl_3 (38 mg, 0.285 mmol) and anisole (41 μl , 0.375 mmol), stirred for 17 h at 22°, and treated with H_2O (15 ml). The mixture was diluted with AcOEt (15 ml). After extraction with H_2O , the aq. layer was evaporated. FC (AcOEt/MeOH/ H_2O 1:0:0 \rightarrow 20:1:1) and drying yielded **41** (5.9 mg, ca. 72%) as a white foam containing substantial amounts of MeOH and H_2O . The sample for microanalysis was dried for 4 d at 10^{-4} Torr.

b) A soln. of **37** (30.7 mg, 43.1 μmol) in CH_2Cl_2 (1.1 ml) was treated at -78° with 1*M* BCl_3 in CH_2Cl_2 (0.8 ml, 0.80 mmol), stirred until the mixture had reached a temp. of 20° (ca. 5.5 h), cooled to -78° , treated with H_2O (2 ml), and evaporated. FC (AcOEt/MeOH/ H_2O 1:0:0 \rightarrow 20:1:1) gave **41** (10.7 mg, ca. 70%) containing substantial amounts of MeOH and H_2O .

Data of 41: R_f (AcOEt/MeOH/ H_2O 10:1:1) 0.17. $[\alpha]_D^{25} = -24.3$ ($c = 0.48$, MeOH). UV (MeOH): 307 (3.99), 219 (4.09), 204 (4.15). IR (KBr): 3600–2400s (br.), 2928m, 1631w, 1606m, 1593s, 1510s, 1459m, 1383m, 1344s, 1299m, 1259s, 1177m, 1112s, 986m, 902w, 870m, 846m. $^1\text{H-NMR}$ (CD_3OD , 300 MHz): 3.82 (*dd*, $J = 3.7$, 9.0, $\text{H}-\text{C}(7)$); 3.84–3.94 (*m*, $\text{H}-\text{C}(5)$, $\text{CH}-\text{C}(5)$); 4.06–4.22 (*m*, $\text{H}-\text{C}(6)$, $\text{CH}'-\text{C}(5)$); 4.83 (*d*, $J = 3.7$, $\text{H}-\text{C}(8)$); 5.10 (br. s, $\text{CH}_2-\text{C}(2)$); 7.11–7.18 (*m*, $J_{\text{vic}} = 9.3$, $\text{H}-\text{C}(2)$ and $\text{H}-\text{C}(6)$ of $\text{C}_6\text{H}_4\text{NO}_2$); 7.50 (*s*, $\text{H}-\text{C}(3)$); 8.16–

8.23 (*m*, $J_{\text{vic}} = 9.3$, H–C(3) and H–C(5) of $\text{C}_6\text{H}_4\text{NO}_2$). ^{13}C -NMR (CD_3OD , 75 MHz): see Table 6; additionally, 65.41 (*t*, $\text{CH}_2\text{--C}(2)$); 116.06 (*d*, C(2) and C(6) of $\text{C}_6\text{H}_4\text{NO}_2$); 126.78 (*d*, C(3) and C(5) of $\text{C}_6\text{H}_4\text{NO}_2$); 142.83 (*s*, C(4) of $\text{C}_6\text{H}_4\text{NO}_2$); 165.26 (*s*, C(1) of $\text{C}_6\text{H}_4\text{NO}_2$). HR-MALDI-MS: 374.0957 (5, $\text{C}_{15}\text{H}_{17}\text{N}_3\text{NaO}_7$, $[\text{M} + \text{Na}]^+$; calc. 374.0964), 360.1163 (6, $\text{C}_{15}\text{H}_{19}\text{N}_3\text{NaO}_6$, $[\text{M} + \text{Na} - \text{O}_2 + \text{H}_2\text{O}]^+$; calc. 360.1171), 358.0997 (7, $\text{C}_{15}\text{H}_{17}\text{N}_3\text{NaO}_6$, $[\text{M} + \text{Na} - \text{O}]^+$; calc. 358.1015), 352.1138 (27, $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}_7$, $[\text{M} + \text{H}]^+$; calc. 352.1145), 338.1350 (38, $\text{C}_{15}\text{H}_{20}\text{N}_3\text{O}_6$, $[\text{M} + \text{H} - \text{O}_2 + \text{H}_2\text{O}]^+$; calc. 338.1350), 336.1191 (28, $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}_6$, $[\text{M} + \text{H} - \text{O}]^+$; calc. 336.1195), 320.1237 (16, $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}_5$, $[\text{M} + \text{H} - \text{O}_2]^+$; calc. 320.1246), 302.1130 (5, $\text{C}_{15}\text{H}_{16}\text{N}_3\text{O}_4$, $[\text{M} - \text{O}_2 - \text{OH}]^+$; calc. 302.1141), 235.0681 (10, $\text{C}_9\text{H}_{12}\text{N}_2\text{NaO}_4$, $[\text{M} + \text{Na} - \text{C}_6\text{H}_5\text{NO}_3]^+$; calc. 235.0695), 213.0866 (100, $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_4$, $[\text{M} - \text{C}_6\text{H}_4\text{NO}_3]^+$; calc. 213.0875). Anal. calc. for $\text{C}_{15}\text{H}_{17}\text{N}_3\text{O}_7 \cdot 0.5 \text{ MeOH} \cdot 0.5 \text{ H}_2\text{O}$ (376.34): C 49.47, H 5.36, N 11.17; found: C 49.57, H 5.25, N 10.95.

(5R,6R,7S,8R)-2-[(2,4-Dinitrophenoxy)methyl]-5,6,7,8-tetrahydro-5-(hydroxymethyl)imidazo[1,2-a]pyridine-6,7,8-triol (**42**). A soln. of **38** (27 mg, 35.7 μmol) in CH_2Cl_2 (1.6 ml) was treated with AlCl_3 (60 mg, 0.450 mmol) and anisole (63 μl , 0.577 mmol), stirred for 17 h at 22°, and treated with H_2O (20 ml). The mixture was diluted with AcOEt (25 ml). After extraction with H_2O , the aq. layer was evaporated. FC (AcOEt/MeOH/ H_2O 1:0:0 \rightarrow 15:1:1) yielded pure **42** (7.6 mg, 75%; colourless solid) which partially decomposed before the NMR measurement. R_f (AcOEt/MeOH/ H_2O 15:1:1) 0.13. IR (KBr): 3600–2400s (br.), 2930m, 1955w, 1837w, 1603s, 1564s, 1525s, 1478m, 1432m, 1373m, 1330s, 1265s, 1169m, 1133s, 1096m, 1060m, 998m, 925m, 834m, 751m, 714m. ^1H -NMR (CD_3OD , 300 MHz, 3:1 mixture of **42** and a product missing the dinitrophenoxy group): 3.83 (*dd*, $J = 3.7, 9.0$, H–C(7)); 3.86–3.95 (*m*, H–C(5), CH–C(5)); 4.07–4.20 (*m*, H–C(6), CH–C(5)); 4.83 (*d*, $J = 3.7$, H–C(8)); 5.29 (br. *s*, $\text{CH}_2\text{--C}(2)$); 7.56 (*s*, H–C(3)); 7.67 (*d*, $J = 9.3$, H–C(6) of $\text{C}_6\text{H}_3\text{N}_2\text{O}_4$); 8.47 (*dd*, $J = 2.8, 9.3$, H–C(5) of $\text{C}_6\text{H}_3\text{N}_2\text{O}_4$); 8.69 (*d*, $J = 2.8$, H–C(3) of $\text{C}_6\text{H}_3\text{N}_2\text{O}_4$). HR-MALDI-MS: 396.9894 (24, $\text{C}_{15}\text{H}_{17}\text{N}_4\text{O}_9$, $[\text{M} + \text{H}]^+$; calc. 397.0995), 213.0865 (100, $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_4$, $[\text{M} - \text{C}_6\text{H}_3\text{N}_2\text{O}_5]^+$; calc. 213.0875).

(5R,6R,7S,8R)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-[(3-nitrophenoxy)methyl]imidazo[1,2-a]pyridine-6,7,8-triol (**43**). A soln. of **39** (9.7 mg, 13.6 μmol) in CH_2Cl_2 (0.6 ml) was treated with AlCl_3 (22 mg, 0.165 mmol) and anisole (24 μl , 0.220 mmol), stirred for 13 h at 22°, and treated with H_2O (10 ml). The mixture was diluted with AcOEt (10 ml). After extraction with H_2O , the aq. layer was evaporated. FC (AcOEt/MeOH/ H_2O 1:0:0 \rightarrow 20:1:1 \rightarrow 15:1:1) yielded **43** (2.6 mg, ca. 54%) as a white solid containing substantial amounts of MeOH. The sample for microanalysis was dried for 4 d at 10^{-4} Torr. R_f (AcOEt/MeOH/ H_2O 10:1:1) 0.23. $[\alpha]_{\text{D}}^{25} = -14.2$ ($c = 0.29$, MeOH). UV (MeOH): 267 (3.68), 214 (4.25). IR (KBr): 3600–2400s (br.), 2925m, 2851m, 1616m, 1528s, 1482m, 1460m, 1384m, 1351s, 1323m, 1285m, 1244m, 1181w, 1095m, 1029w, 1007m, 903w, 843w, 825w, 796w, 737m. ^1H -NMR (CD_3OD , 300 MHz): 3.81 (*dd*, $J = 3.7, 9.3$, irradi. at 4.11 \rightarrow *d*, $J \approx 4.0$, irradi. at 4.83 \rightarrow *d*, $J = 9.3$, H–C(7)); 3.84–3.90 (*m*, H–C(5)); 3.90 (*dd*, $J = 5.6, 10.9$, CH–C(5)); 4.06–4.22 (*m*, H–C(6), CH–C(5)); 4.83 (*d*, $J = 3.7$, irradi. at 3.81 \rightarrow *s*, H–C(8)); 5.08 (br. *s*, $\text{CH}_2\text{--C}(2)$); 7.39 (*ddd*, $J = 0.9, 2.5, 8.4$, H–C(6) of $\text{C}_6\text{H}_4\text{NO}_2$); 7.49 (*s*, H–C(3)); 7.50 (*t*, $J = 8.4$, H–C(5) of $\text{C}_6\text{H}_4\text{NO}_2$); 7.81 (*ddd*, $J = 0.9, 2.2, 8.7$, H–C(4) of $\text{C}_6\text{H}_4\text{NO}_2$); 7.82 (*t*, $J \approx 1.9$, H–C(2) of $\text{C}_6\text{H}_4\text{NO}_2$). ^{13}C -NMR (CD_3OD , 75 MHz): see Table 6; additionally, 65.30 (*t*, $\text{CH}_2\text{--C}(2)$); 110.27 (*d*, C(2) of $\text{C}_6\text{H}_4\text{NO}_2$); 116.48 (*d*, C(4) of $\text{C}_6\text{H}_4\text{NO}_2$); 122.56 (*d*, C(6) of $\text{C}_6\text{H}_4\text{NO}_2$); 131.19 (*d*, C(5) of $\text{C}_6\text{H}_4\text{NO}_2$); 150.39 (*s*, C(3) of $\text{C}_6\text{H}_4\text{NO}_2$); 160.47 (*s*, C(1) of $\text{C}_6\text{H}_4\text{NO}_2$). HR-MALDI-MS: 374.0952 (39, $\text{C}_{15}\text{H}_{17}\text{N}_3\text{NaO}_7$, $[\text{M} + \text{Na}]^+$; calc. 374.0964), 360.1168 (65, $\text{C}_{15}\text{H}_{19}\text{N}_3\text{NaO}_6$, $[\text{M} + \text{Na} - \text{O}_2 + \text{H}_2\text{O}]^+$; calc. 360.1171), 358.1018 (67, $\text{C}_{15}\text{H}_{17}\text{N}_3\text{NaO}_6$, $[\text{M} + \text{Na} - \text{O}]^+$; calc. 358.1015), 352.1143 (70, $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}_7$, $[\text{M} + \text{H}]^+$; calc. 352.1145), 338.1347 (100, $\text{C}_{15}\text{H}_{20}\text{N}_3\text{O}_6$, $[\text{M} + \text{H} - \text{O}_2 + \text{H}_2\text{O}]^+$; calc. 338.1352), 336.1191 (96, $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}_6$, $[\text{M} + \text{H} - \text{O}]^+$; calc. 336.1195), 320.1234 (82, $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}_5$, $[\text{M} + \text{H} - \text{O}_2]^+$; calc. 320.1246), 213.0868 (90, $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_4$, $[\text{M} - \text{C}_6\text{H}_4\text{NO}_3]^+$; calc. 213.0875), 195.0758 (61, $\text{C}_9\text{H}_{11}\text{N}_2\text{O}_3$, $[\text{M} - \text{C}_6\text{H}_4\text{NO}_3 - \text{H}_2\text{O}]^+$; calc. 195.0770). Anal. calc. for $\text{C}_{15}\text{H}_{17}\text{N}_3\text{O}_7 \cdot \text{MeOH}$ (383.36): C 50.13, H 5.52, N 10.96; found: C 50.34, H 5.36, N 10.94.

Methyl and Ethyl (5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylate (**44** and **45**, resp.). *a*) A soln. of **20** (210 mg, 0.306 mmol) in THF (10 ml) was cooled to -78° , treated with a 1.44M soln. of BuLi¹⁴) in hexane (0.48 ml, 0.691 mmol), stirred for 1 h, treated with ClCOOMe (0.20 ml, 2.60 mmol), stirred for 1 h at -78° , and for another 17 h at 22°. The mixture was treated with sat. NH_4Cl soln. (10 ml) and diluted with Et_2O (40 ml). The layers were separated, and the Et_2O layer was washed with sat. NH_4Cl soln. (2×20 ml). The combined aq. layers were extracted with Et_2O (2×15 ml). The combined org. layers were washed with H_2O (40 ml), brine (40 ml), and dried (MgSO_4). Evaporation and FC (hexane/AcOEt 1:0 \rightarrow 7:3 \rightarrow 1:1) yielded **44** (82 mg, 43%) and **17** (41 mg, 24%). Oils.

¹⁴) The molar concentration of BuLi was determined by titration of Ph_2CHCOOH as described by Kofron and Baclawski [58].

b) A suspension of **22** (75 mg, 0.127 mmol), MnO₂ (285 mg, 3.28 mmol, Aldrich 21,764-6) and NaCN (35 mg, 0.714 mmol) in MeOH (4 ml) was treated with AcOH (20 µl, 0.350 mmol), stirred at 22° for 12 h, filtered through *Celite* (washing with 20 ml of MeOH and 20 ml of AcOEt). Evaporation of the filtrate and FC (hexane/AcOEt 1:0 → 2:1 → 1:1) gave **45** (17.1 mg, 21%) and **44** (51.6 mg, 65%). Colourless oils.

c) As described in *b*. After evaporation of the filtrate, the crude product was diluted with AcOEt (60 ml) and washed with sat. NaHCO₃ soln. (3 × 30 ml). The combined aq. layers were extracted with AcOEt (2 × 40 ml). The combined org. layers were washed with H₂O (70 ml) and brine (70 ml), dried (MgSO₄), filtered, and evaporated. FC (cyclohexane/AcOEt 1:0 → 1:1) afforded **44** (78%) as a single product.

Data of 44: *R*_f (hexane/AcOEt 1:1) 0.35. [α]_D²⁵ = -37.1 (*c* = 1.00, CHCl₃). UV (CHCl₃): 243 (3.98). IR (CHCl₃): 3090w, 3068w, 3024m, 3018m, 2953m, 2928w, 2869w, 1952w, 1876w, 1811w, 1718s, 1603w, 1552m, 1497m, 1455m, 1428w, 1363m, 1343m, 1327m, 1262m, 1217s, 1146m, 1097s, 1028s, 1010s, 943w, 913w. ¹H-NMR (CDCl₃, 300 MHz): see *Table 7*; additionally, 3.91 (s, MeO); 4.45 (br. s, PhCH₂); 4.62 (*d*, *J* = 11.2, PhCH); 4.64 (*d*, *J* = 12.1, PhCH); 4.66 (*d*, *J* = 11.5, PhCH); 4.70 (*d*, *J* = 12.1, PhCH); 4.74 (*d*, *J* = 11.8, PhCH); 4.99 (*d*, *J* = 11.2, PhCH); 7.23–7.38 (*m*, 20 arom. H). ¹³C-NMR (CDCl₃, 75 MHz): see *Table 5*; additionally, 51.80 (*q*, MeO); 70.45, 70.93 (2*t*, PhCH₂, CH₂-C(5)); 71.95 (*t*, PhCH₂); 73.23 (*t*, PhCH₂); 74.92 (*t*, PhCH₂); 127.44–128.44 (several *d*); 137.07, 137.49, 137.65, 137.80 (4*s*); 163.12 (*s*, C=O). HR-MALDI-MS: 657.2380 (4, C₃₈H₃₈KN₂O₆, [*M* + *K*]⁺; calc. 657.2367), 641.2586 (77, C₃₈H₃₈N₂NaO₆, [*M* + *Na*]⁺; calc. 641.2627), 619.2809 (100, C₃₈H₃₉N₂O₆, [*M* + *H*]⁺; calc. 619.2808), 587.2574 (3, C₃₇H₃₅N₂O₅, [*M* - MeO]⁺; calc. 587.2546), 511.2265 (31, C₃₁H₃₁N₂O₅, [*M* - BnO]⁺; calc. 511.2232), 479.2002 (15, C₃₀H₂₇N₂O₄, [*M* - BnO - MeOH]⁺; calc. 479.1970). Anal. calc. for C₃₈H₃₈N₂O₆ (618.73): C 73.77, H 6.19, N 4.53; found: C 73.79, H 6.33, N 4.64.

Data of 45: *R*_f (hexane/AcOEt 1:1) 0.53. [α]_D²⁵ = -35.6 (*c* = 0.58, CHCl₃). UV (CHCl₃): 242 (4.01). IR (CHCl₃): 3159w, 3090w, 3068w, 3019m, 2963m, 2929w, 2870w, 1953w, 1878w, 1811w, 1717m, 1603w, 1550w, 1497w, 1455m, 1393w, 1367m, 1338w, 1323m, 1262m, 1217s, 1146m, 1096s, 1027s, 930w, 913w. ¹H-NMR (CDCl₃, 300 MHz): see *Table 7*; additionally, 1.36 (*t*, *J* = 7.2, MeCH₂); 4.34 (*q*, *J* = 7.2, MeCH₂); 4.42 (br. s, PhCH₂); 4.58 (*d*, *J* = 11.2, PhCH); 4.60 (*d*, *J* = 12.1, PhCH); 4.62 (*d*, *J* = 11.5, PhCH); 4.66 (*d*, *J* = 11.2, PhCH); 4.70 (*d*, *J* = 12.1, PhCH); 4.95 (*d*, *J* = 11.2, PhCH); 7.20–7.35 (*m*, 20 arom. H). ¹³C-NMR (CDCl₃, 75 MHz): see *Table 5*; additionally, 14.46 (*q*, MeCH₂); 60.53 (*t*, MeCH₂); 70.48, 70.86 (2*t*, PhCH₂, CH₂-C(5)); 71.89 (*t*, PhCH₂); 73.22 (*t*, PhCH₂); 74.90 (*t*, PhCH₂); 127.51–128.50 (several *d*); 137.19, 137.58, 137.77, 137.93 (4*s*); 162.87 (*s*, C=O). MALDI-MS: 655 ([*M* + *Na*]⁺), 633 ([*M* + *H*]⁺). HR-MALDI-MS: 671.2537 (9, C₃₉H₄₀KN₂O₆, [*M* + *K*]⁺; calc. 671.2523), 655.2787 (100, C₃₉H₄₀N₂NaO₆, [*M* + *Na*]⁺; calc. 655.2784), 633.2966 (54, C₃₉H₄₁N₂O₆, [*M* + *H*]⁺; calc. 633.2964), 587.2550 (7, C₃₇H₃₅N₂O₅, [*M* - EtO]⁺; calc. 587.2546), 525.2393 (26, C₃₂H₃₃N₂O₅, [*M* - BnO]⁺; calc. 525.2389), 479.1981 (19, C₃₀H₂₇N₂O₄, [*M* - BnO - EtOH]⁺; calc. 479.1971). Anal. calc. for C₃₉H₄₀N₂O₆ (632.75): C 74.03, H 6.37, N 4.43; found: C 74.18, H 6.50, N 4.23.

Methyl (5R,6R,7S,8R)-5,6,7,8-Te trahydro-6,7,8-trihydroxy-5-(hydroxymethyl)imidazo[1,2-a]pyridine-2-carboxylate (46). A soln. of **44** (105 mg, 0.170 mmol) in AcOEt/MeOH 1:1 (1.8 ml) was treated with AcOH (0.9 ml) and 10% Pd/C (50 mg), hydrogenated at 6 bar for 48 h, and filtered through *Celite* (washing with MeOH/H₂O 9:1 (20 ml)). Evaporation of the combined filtrates, FC (AcOEt/MeOH/H₂O 1:0:0 → 10:1:1), lyophilisation, and drying gave **46** (38.5 mg, ca. 88%) as a colourless hygroscopic resin containing substantial amounts of MeOH and H₂O. The sample for microanalysis was dried for 4 d at 10⁻⁴ Torr. *R*_f (AcOEt/MeOH/H₂O 10:1:1) 0.12. [α]_D²⁵ = -21.6 (*c* = 1.02, MeOH). UV (MeOH): 238 (3.95), 200 (3.67). IR (KBr): 3600–2400s (br.), 2952m, 2924m, 1716s, 1636w, 1553m, 1442m, 1356m, 1334m, 1219s, 1138m, 1095s, 1011m, 945w, 902w, 834w, 805w, 769m. ¹H-NMR (CD₃OD, 300 MHz): 3.83 (s, MeO); 3.84 (*dd*, *J* ≈ 3.7, 8.7, irradi. at 4.11 → change, irradi. at 4.84 → *d*, *J* = 9.0, H-C(7)); 3.89 (*dd*, *J* = 5.9, 11.2, irradi. at 4.17 → change, CH-C(5)); 3.90–3.97 (*m*, irradi. at 4.11 → change, irradi. at 4.17 → change, H-C(5)); 4.11 (*dd*, *J* = 7.2, 9.0, irradi. at 3.84 → *d* *J* ≈ 6.5, H-C(6)); 4.17 (*dd*, *J* = 2.2, 11.2, CH'-C(5)); 4.84 (*d*, *J* = 3.7, irradi. at 3.84 → *s*, H-C(8)); 8.01 (*s*, H-C(3)). ¹³C-NMR (CD₃OD, 75 MHz): see *Table 6*; additionally, 51.95 (*q*, MeO); 164.34 (*s*, C=O). HR-MALDI-MS: 281.0742 (100, C₁₀H₁₄N₂NaO₆, [*M* + *Na*]⁺; calc. 281.0749), 259.0928 (60, C₁₀H₁₅N₂O₆, [*M* + *H*]⁺; calc. 259.0930), 227.0658 (21, C₉H₁₁N₂O₅, [*M* - MeO]⁺; calc. 227.0668). Anal. calc. for C₁₀H₁₄N₂O₆ · 0.6 MeOH · 0.1 H₂O (279.26): C 45.59, H 5.99, N 10.03; found: C 45.45, H 5.70, N 9.77.

(5R,6R,7S,8R)-5,6,7,8-Tetrahydro-6,7,8-trihydroxy-5-(hydroxymethyl)imidazo[1,2-a]pyridine-2-carboxylic Acid (47). A soln. of **46** (25 mg, 96.8 µmol) in 0.4*M* soln. of KOH in EtOH/H₂O 4:1 (1 ml) was heated at 50° for 3 h, evaporated, taken up in H₂O (3 ml), and applied to ion-exchange chromatography (*Amberlite CG-120*, H⁺ form, elution with 0.1*M* aq. NH₃). Lyophilisation gave **47** (19.5 mg, 83%) as a colourless hygroscopic resin. *R*_f (AcOEt/MeOH/H₂O 3:1:1) 0.13. [α]_D²⁵ = -51.3 (*c* = 0.74, H₂O). UV (H₂O): 226 (3.96), 193 (3.99). IR (KBr): 3600–2400s (br.), 2918m, 2857m, 1619s, 1575s, 1544s, 1434m, 1398s, 1337m, 1265m, 1183m, 1094s, 1065s, 1000m, 902m, 835m, 775m, 724m. ¹H-NMR (D₂O, 300 MHz): 3.84 (*dd*, *J* = 3.4, 9.7, H-C(7)); 3.82–3.89 (*m*, H-C(5));

3.89 (*dd*, $J = 3.4$, 12.1, CH–C(5)); 4.04–4.14 (*m*, H–C(6), CH'–C(5)); 4.79 (*d*, $J = 3.4$, H–C(8)); 7.53 (*s*, H–C(3)). $^{13}\text{C-NMR}$ (D_2O , 75 MHz): see Table 6; additionally, 169.88 (*s*, C=O). HR-MALDI-MS: 289.0405 (12, $\text{C}_9\text{H}_{11}\text{N}_2\text{Na}_2\text{O}_6$, $[\text{M} - \text{H} + 2 \text{Na}]^+$; calc. 289.0412); 267.0584 (51, $\text{C}_9\text{H}_{12}\text{N}_2\text{NaO}_6$, $[\text{M} + \text{Na}]^+$; calc. 267.0593); 245.0768 (100, $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_6$, $[\text{M} + \text{H}]^+$; calc. 245.0774), 227.0657 (23, $\text{C}_9\text{H}_{11}\text{N}_2\text{O}_5$, $[\text{M} - \text{OH}]^+$; calc. 227.0668).

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carbonitrile (**48**). a) A soln. of **20** (235 mg, 0.342 mmol) in THF (2.3 ml) was treated at 0° with 1M EtMgBr soln. in THF (1.18 ml, 1.18 mmol), stirred under Ar for 15 min, treated with a suspension of TsCN (620 mg, 3.42 mmol) in THF (4.7 ml), and stirred at $0^\circ \rightarrow 23^\circ$ for 4 h. The mixture was cooled to 0° , treated with sat. NH_4Cl soln. (10 ml), diluted with Et_2O (50 ml), and washed with sat. NH_4Cl soln. (3×30 ml). The combined aq. layers were extracted with Et_2O (2×20 ml). The combined org. layers were washed with H_2O (50 ml) and brine (50 ml), dried (MgSO_4), filtered, and evaporated. FC (hexane/AcOEt 5:1 \rightarrow 3:1) gave **48** (147 mg, 73%). Colourless oil.

b) A suspension of **20** (50 mg, 72.8 μmol), $\text{Zn}(\text{CN})_2$ (17 mg, 0.145 mmol) and $[\text{Pd}(\text{PPh}_3)_4]$ (25 mg, 21.6 μmol) in degassed DMF (0.2 ml) was stirred at 150° for 1 h. The mixture was cooled to r.t., diluted with AcOEt (15 ml), and washed with sat. NH_4Cl soln. (3×10 ml). The combined aq. layers were extracted with AcOEt (2×15 ml). The combined org. layers were washed with H_2O (20 ml) and brine (20 ml), dried (MgSO_4), filtered, and evaporated. FC (hexane/AcOEt 2:1 \rightarrow 1:1 \rightarrow 0:1) gave **48** (17 mg, 40%) and **17** (11 mg, 27%).

Data of **48**: R_f (hexane/AcOEt 2:1) 0.60. $[\alpha]_D^{25} = -43.1$ ($c = 1.02$, CHCl_3). UV (CHCl_3): 259 (3.02), 240 (3.55). IR (CHCl_3): 3157w, 3090w, 3068w, 3024m, 3016m, 2927w, 2870m, 2238m, 1952w, 1879w, 1811w, 1730w, 1603w, 1531w, 1497w, 1455m, 1364m, 1266m, 1098s, 1028s, 913w. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): see Table 7; additionally, 4.43 (*d*, $J = 12.5$, PhCH); 4.47 (*d*, $J = 12.8$, PhCH); 4.56 (*d*, $J = 12.1$, PhCH); 4.60 (*d*, $J = 12.8$, PhCH); 4.65 (*d*, $J = 12.1$, PhCH); 4.68 (*d*, $J = 11.5$, PhCH); 4.76 (*d*, $J = 12.8$, PhCH); 4.94 (*d*, $J = 11.2$, PhCH); 7.22–7.44 (*m*, 20 arom. H). $^{13}\text{C-NMR}$ (CDCl_3 , 75 MHz): see Table 5; additionally, 70.49, 71.00 (2t, PhCH₂, CH₂–C(5)); 72.06 (*t*, PhCH₂); 73.34 (*t*, PhCH₂); 74.78 (*t*, PhCH₂); 114.11, 114.76 (2s, C(2), C \equiv N); 127.72–128.52 (several *d* incl. C(3)); 136.77 (*s*), 137.22 (2s), 137.34 (*s*). HR-MALDI-MS: 624.2254 (4, $\text{C}_{37}\text{H}_{35}\text{KN}_3\text{O}_4$, $[\text{M} + \text{K}]^+$; calc. 624.2264); 608.2527 (100, $\text{C}_{37}\text{H}_{35}\text{N}_3\text{NaO}_4$, $[\text{M} + \text{Na}]^+$; calc. 608.2525); 586.2707 (62, $\text{C}_{37}\text{H}_{36}\text{N}_3\text{O}_4$, $[\text{M} + \text{H}]^+$; calc. 586.2706); 478.2111 (53, $\text{C}_{30}\text{H}_{28}\text{N}_3\text{O}_3$, $[\text{M} - \text{BnO}]^+$; calc. 478.2131). Anal. calc. for $\text{C}_{37}\text{H}_{35}\text{N}_3\text{O}_4$ (585.71): C 75.88, H 6.02, N 7.17; found: C 75.90, H 6.12, N 7.24.

(5R,6R,7S,8R)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-5,6,7,8-tetrahydro-2-(1H-tetrazol-5-yl)imidazo[1,2-a]pyridine (**49**). At 0° , a soln. of 2M Me_3Al in toluene (0.34 ml, 0.68 mmol) in toluene (1 ml) was treated with Me_2SiN_3 (90 μl , 0.684 mmol), stirred for 10 min, and treated dropwise with a soln. of **48** (81 mg, 0.138 mmol) in toluene (1 ml). The mixture was stirred at 80° for 1.5 h, cooled to 0° , treated with sat. NH_4Cl soln. (5 ml), diluted with AcOEt (40 ml), and washed with sat. NH_4Cl soln. (3×30 ml). The combined aq. layers were extracted with AcOEt (2×25 ml). The combined org. layers were washed with H_2O (50 ml) and brine (50 ml), dried (Na_2SO_4), filtered, and evaporated. The crude product (77 mg, a single compound according to the $^1\text{H-NMR}$ spectrum) was precipitated from hexane/AcOEt 3:1 (4 ml) at -50° to afford after drying **49** (66 mg, ca. 76%) as a colourless solid containing substantial amounts of H_2O . The sample for microanalysis was dried for 4 d at 10^{-4} Torr. R_f (AcOEt/MeOH 5:1) 0.21. R_f ($\text{CHCl}_3/\text{MeOH}/\text{AcOH}$ 16:1:1) 0.61. M.p. 116.2–118.1 $^\circ$. $[\alpha]_D^{25} = +7.9$ ($c = 0.79$, CHCl_3). UV (CHCl_3): 248 (4.21). IR (CHCl_3): 3200–2400m (br.), 3163w, 3089m, 3067m, 3033m, 3011m, 2959m, 2905m, 2867m, 1952w, 1878w, 1812w, 1629m, 1527w, 1496m, 1454m, 1421w, 1364m, 1337m, 1262s, 1097s, 1026s, 963m, 912w. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): see Table 7; additionally, 4.51 (br. s, PhCH₂); 4.52 (*d*, $J = 12.1$, PhCH); 4.63 (*d*, $J = 12.1$, PhCH); 4.64 (*d*, $J = 11.2$, PhCH); 4.71 (*d*, $J = 12.1$, PhCH); 4.84 (*d*, $J = 11.8$, PhCH); 4.98 (*d*, $J = 11.5$, PhCH); 7.01–7.03 (*m*, 3 arom. H); 7.07–7.10 (*m*, 2 arom. H); 7.24–7.36 (*m*, 13 arom. H); 7.39–7.42 (*m*, 2 arom. H). $^{13}\text{C-NMR}$ (CDCl_3 , 75 MHz): see Table 5; additionally, 70.07, 71.45 (2t, PhCH₂, CH₂–C(5)); 72.04 (*t*, PhCH₂); 73.39 (*t*, PhCH₂); 74.73 (*t*, PhCH₂); 127.37–128.50 (several *d*); 136.89 (2s); 137.14, 137.44 (2s); 149.32 (*s*, C(5) of CHN_4). HR-MALDI-MS: 673.2530 (6, $\text{C}_{37}\text{H}_{35}\text{N}_6\text{Na}_2\text{O}_4$, $[\text{M} - \text{H} + 2 \text{Na}]^+$; calc. 673.2515), 651.2730 (93, $\text{C}_{37}\text{H}_{36}\text{N}_6\text{NaO}_4$, $[\text{M} + \text{Na}]^+$; calc. 651.2696), 629.2878 (100, $\text{C}_{37}\text{H}_{37}\text{N}_6\text{O}_4$, $[\text{M} + \text{H}]^+$; calc. 629.2876), 623.2647 (48, $\text{C}_{37}\text{H}_{36}\text{N}_4\text{NaO}_4$, $[\text{M} - \text{N}_2 + \text{Na}]^+$; calc. 623.2634), 601.2822 (62, $\text{C}_{37}\text{H}_{37}\text{N}_4\text{O}_4$, $[\text{M} + \text{H} - \text{N}_2]^+$; calc. 601.2815), 572.2656 (10, $\text{C}_{37}\text{H}_{36}\text{N}_2\text{O}_4$, $[\text{M} - 2 \text{N}_2]^+$; calc. 572.2675), 521.2292 (6, $\text{C}_{30}\text{H}_{29}\text{N}_6\text{O}_3$, $[\text{M} - \text{BnO}]^+$; calc. 521.2301), 493.2235 (58, $\text{C}_{30}\text{H}_{29}\text{N}_4\text{O}_3$, $[\text{M} - \text{BnO} - \text{N}_3]^+$; calc. 493.2239), 464.2089 (14, $\text{C}_{30}\text{H}_{28}\text{N}_2\text{O}_3$, $[\text{M} - \text{BnOH} - 2 \text{N}_2]^+$; calc. 464.2100). Anal. calc. for $\text{C}_{37}\text{H}_{35}\text{N}_3\text{O}_4 \cdot 1.5 \text{H}_2\text{O}$ (655.76): C 67.77, H 5.99, N 12.82; found: C 68.03, H 6.04, N 12.82.

(5R,6R,7S,8R)-5,6,7,8-Tetrahydro-5-(hydroxymethyl)-2-(1H-tetrazol-5-yl)imidazo[1,2-a]pyridine-6,7,8-triol (**50**). A soln. of **49** (35 mg, 55.7 μmol) in CH_2Cl_2 (1.4 ml) was treated at -78° with 1M BCl_3 in CH_2Cl_2 (0.88 ml, 0.88 mmol), stirred until the mixture had reached a temp. of 10° (ca. 5 h), cooled to -78° , treated with H_2O (2 ml), and evaporated. The residue was taken up in H_2O (3 ml) and applied to ion-exchange column

(Amberlite CG-120, H⁺ form, elution with 0.1M aq. NH₃). Lyophilisation gave **50** (12.7 mg, 85%). Colourless hygroscopic resin. *R_f* (AcOEt/MeOH/AcOH 7:5:1) 0.10. [α]_D²⁵ = –33.8 (*c* = 0.57, MeOH). UV (MeOH): 233 (3.91). IR (KBr): 3600–2400s (br.), 2930m, 1630m, 1519w, 1452m, 1401m, 1333m, 1246m, 1200m, 1097s, 965w, 904m, 873w. ¹H-NMR (D₂O, 300 MHz): 3.98–4.06 (*m*, irradi. at 5.00 → change, H–C(7), H–C(5)); 4.08 (*dd*, *J* = 3.1, 13.7, CH–C(5)); 4.23–4.33 (*m*, H–C(6), CH'–C(5)); 5.00 (*d*, *J* = 3.4, H–C(8)); 7.74 (*s*, H–C(3)). ¹³C-NMR (D₂O, 75 MHz): see Table 6; *s* for CHN₄ hidden by the noise. HR-MALDI-MS: 313.0307 (15, C₉H₁₁N₆Na₂O₄, [*M* – H + 2 Na]⁺; calc. 313.0637), 291.0807 (38, C₉H₁₂N₆NaO₄, [*M* + Na]⁺; calc. 291.0818), 269.0991 (100, C₉H₁₃N₆O₄, [*M* + H]⁺; calc. 269.0998), 241.0933 (21, C₉H₁₃N₄O₄, [*M* + H – N₂]⁺; calc. 241.0937), 212.1441 (90, C₉H₁₂N₂O₄, [*M* – 2 N₂]⁺; calc. 212.0797), 198.9984 (53, C₈H₁₁N₂O₄, [*M* – CHN₄]⁺; calc. 199.0719).

Inhibition Studies. Determination of the inhibition constants (*K_i*) or the *IC*₅₀ values was performed with a range of inhibitor concentrations (typically 4–7 concentrations), which bracket the *K_i* or *IC*₅₀ value, and substrate concentrations, which bracket the *K_M* value of each enzyme (for *K_i*, typically 5–7 concentrations), or correspond to it (for *IC*₅₀).

a) Inhibition of Snail β-Mannosidase. *K_M* = 0.42–0.80. Inhibition constants (*K_i*) and *IC*₅₀ values were determined at 25° at an enzyme concentration of 0.048 units/ml, with a 0.05M acetate buffer (pH 4.5) and 4-nitrophenyl β-D-mannopyranoside as the substrate. The enzymatic reaction was started after incubation of the enzyme (100 μl) in presence of the inhibitor (50 μl) during 1 h at 25°, by the addition of the substrate (50 μl). The enzyme reaction was quenched by addition of 0.2M borate buffer (pH 9.2, 100 μl) after 5 min, and the absorption at 405 nm was taken as rate for the hydrolysis of the substrate. *IC*₅₀ Values were determined by plotting the reciprocal value of the rate of substrate hydrolysis vs. the inhibitor concentration. After fitting a straight line to the data by linear regression, the negative [*I*] intercept of this plot provided the appropriate *IC*₅₀ value. *K_i* Values were determined by taking the slopes from the *Lineweaver–Burk* plots [59] and plotting them vs. the inhibitor concentrations [60]. After fitting a straight line to the data by linear regression, the negative [*I*] intercept of this plot provided the appropriate *K_i* value.

b) Inhibition of Jack Beans α-Mannosidase. *K_M* = 1.8–2.8 ([61]: 2.5 mM). As described in *a*, inhibition studies were carried out at 37° at an enzyme concentration of 0.086 units/ml, with a 0.05M acetate buffer (pH 4.5), containing 2 mmol of ZnCl₂ and 4-nitrophenyl α-D-mannopyranoside as the substrate. The enzymatic reaction was started after the incubation at 37° for 1 h.

REFERENCES

- [1] T. Aoyagi, H. Suda, K. Uotani, F. Kojima, T. Aoyama, K. Horiguchi, M. Hamada, T. Takeuchi, *J. Antibiot.* **1992**, *45*, 1404.
- [2] T. Granier, N. Panday, A. Vasella, *Helv. Chim. Acta* **1997**, *80*, 979.
- [3] K. Tatsuta, S. Miura, S. Ohta, H. Gunji, *J. Antibiot.* **1995**, *48*, 286.
- [4] T. D. Heightman, A. Vasella, K. E. Tsitsanou, S. E. Zographos, V. T. Skamnaki, N. G. Oikonomakos, *Helv. Chim. Acta* **1998**, *81*, 853.
- [5] N. Panday, A. Vasella, *Synthesis* **1999**, 1459.
- [6] N. Panday, Y. Canac, A. Vasella, *Helv. Chim. Acta* **2000**, *83*, 58.
- [7] E. Dubost, T. Tschamber, J. Streith, *Tetrahedron Lett.* **2003**, *44*, 3667.
- [8] M. N. Namchuk, S. G. Withers, *Biochemistry* **1995**, *34*, 16194.
- [9] J. D. McCarter, M. J. Adam, S. G. Withers, *Biochem. J.* **1992**, *286*, 721.
- [10] K.-R. Roeser, G. Legler, *Hoppe-Seyler's Z. Physiol. Chem.* **1980**, *361*, 321.
- [11] K.-R. Roeser, G. Legler, *Biochim. Biophys. Acta* **1981**, *657*, 321.
- [12] M. Czjzek, M. Cicek, V. Zamboni, W. P. Burmeister, D. R. Bevan, B. Henrissat, A. Esen, *Biochem. J.* **2001**, *354*, 37.
- [13] S. G. Withers, *Carbohydr. Polym.* **2001**, *44*, 325.
- [14] H. S. Overkleeft, J. van Wiltenburg, U. K. Pandit, *Tetrahedron* **1994**, *50*, 4215.
- [15] K. Tatsuta, S. Miura, H. Gunji, *Bull. Chem. Soc. Jpn.* **1997**, *70*, 427.
- [16] D. R. Williams, D. L. Brown, J. W. Benbow, *J. Am. Chem. Soc.* **1989**, *111*, 1923.
- [17] W. A. Herrmann, C. Brossmer, K. Öfele, C. P. Reisinger, T. Priermeier, M. Beller, H. Fischer, *Angew. Chem., Int. Ed.* **1995**, *34*, 1844.
- [18] K. Sonogashira, Y. Tohda, N. Hagihara, *Tetrahedron Lett.* **1975**, *16*, 4467.
- [19] T. Sakamoto, H. Nagata, Y. Kondo, M. Shiraiwa, H. Yamanaka, *Chem. Pharm. Bull.* **1987**, *35*, 823.
- [20] M. D. Cliff, S. G. Pyne, *Tetrahedron* **1996**, *52*, 13703.

- [21] T. Akiyama, H. Hirofuji, S. Ozaki, *Bull. Chem. Soc. Jpn.* **1992**, *65*, 1932.
- [22] W. S. Wadsworth, W. D. Emmons, *J. Am. Chem. Soc.* **1961**, *83*, 1733.
- [23] M. Larsen, F. C. Krebs, M. Jørgensen, N. Harrit, *J. Org. Chem.* **1998**, *63*, 4420.
- [24] Y. Ishino, M. Mihara, S. Nishihama, I. Nishiguchi, *Bull. Chem. Soc. Jpn.* **1998**, *71*, 2669.
- [25] L. G. Fröhlich, P. Kotsonis, H. Traub, S. Taghavi-Moghadam, N. Al-Masoudi, H. Hofmann, H. Strobel, H. Matter, W. Pfeleiderer, H. H. W. Schmidt, *J. Med. Chem.* **1999**, *42*, 4108.
- [26] P. M. Ruoff, R. C. Scott, *J. Am. Chem. Soc.* **1950**, *72*, 4950.
- [27] H. Tagawa, S. Kubo, F. Ishikawa, *Chem. Pharm. Bull.* **1981**, *29*, 3515.
- [28] J. M. Lehn, F. Schmidt, J. P. Vigneron, *J. Heterocycl. Chem.* **1990**, *27*, 1633.
- [29] R. D. Youssefeyeh, E. Magnien, T. D. Y. Lee, W. K. Chan, C. J. Lin, R. A. Galemno, W. H. Johnson, J. Tan, H. F. Campbell, F. C. Huang, G. W. Nuss, G. W. Carnathan, C. A. Sutherland, R. G. Van Inwegen, *J. Med. Chem.* **1990**, *33*, 1186.
- [30] R. H. Martin, R. Robinson, *J. Chem. Soc.* **1949**, 1866.
- [31] M. Farina, G. Audisio, *Tetrahedron* **1970**, *26*, 1827.
- [32] D. A. Frost, G. A. Morrison, *J. Chem. Soc., Perkin Trans. 1* **1973**, 2159.
- [33] H. Alper, G. Vasapollo, *Tetrahedron Lett.* **1992**, *33*, 7477.
- [34] I. Columbus, M. Haj-Zaroubi, J. S. Siegel, S. E. Biali, *J. Org. Chem.* **1998**, *63*, 9148.
- [35] H. Singh, A. S. Chawla, V. K. Kapoor, D. Paul, R. K. Malhotra, *Prog. Med. Chem.* **1980**, *17*, 151.
- [36] R. J. Herr, *Bioorg. Med. Chem.* **2002**, *10*, 3379.
- [37] E. J. Corey, N. W. Gilman, B. E. Ganem, *J. Am. Chem. Soc.* **1968**, *90*, 5616.
- [38] P. Karuso, W. C. Taylor, *Aust. J. Chem.* **1984**, *37*, 1271.
- [39] W. Kinzy, R. R. Schmidt, *Liebigs Ann. Chem.* **1987**, 407.
- [40] B. Iddon, N. Khan, *J. Chem. Soc., Perkin Trans. 1* **1987**, 1445.
- [41] M. P. Groziak, L. Wei, *J. Org. Chem.* **1992**, *57*, 3776.
- [42] M. W. Holladay, H. Bai, Y. Li, N. H. Lin, J. F. Daanen, K. B. Ryther, J. T. Wasicak, J. F. Kincaid, Y. He, A. M. Hettinger, P. Huang, D. J. Anderson, A. W. Bannon, M. J. Buckley, J. E. Campbell, D. L. Donnelly-Roberts, K. L. Gunther, D. J. B. Kim, T. A. Kuntzweiler, J. P. Sullivan, M. W. Decker, S. P. Arneric, *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2797.
- [43] P. E. Malignes, M. S. Waters, F. Fleitz, D. Askin, *Tetrahedron Lett.* **1999**, *40*, 8193.
- [44] M. Alterman, A. Hallberg, *J. Org. Chem.* **2000**, *65*, 7984.
- [45] B. A. Anderson, E. C. Bell, F. O. Ginah, N. K. Harn, L. M. Pagh, J. P. Wepsiec, *J. Org. Chem.* **1998**, *63*, 8224.
- [46] A. S. Bell, S. F. Campbell, D. S. Morris, D. A. Roberts, M. H. Stefaniak, *J. Med. Chem.* **1989**, *32*, 1552.
- [47] B. E. Huff, M. A. Staszak, *Tetrahedron Lett.* **1993**, *34*, 8011.
- [48] S. J. Wittenberger, B. G. Donner, *J. Org. Chem.* **1993**, *58*, 4139.
- [49] G. W. Danswan, P. W. Hairsine, D. A. Rowlands, J. B. Taylor, R. Westwood, *J. Chem. Soc., Perkin Trans. 1* **1982**, 1049.
- [50] I. R. Ager, A. C. Barnes, G. W. Danswan, P. W. Hairsine, D. P. Kay, P. D. Kennewell, S. S. Matharu, P. Miller, P. Robson, D. A. Rowlands, W. R. Tully, R. Westwood, *J. Med. Chem.* **1988**, *31*, 1098.
- [51] D. P. Matthews, J. R. McCarthy, J. P. Whitten, P. R. Kastner, C. L. Barney, F. N. Marshall, M. A. Ertel, T. Burkhard, P. J. Shea, T. Kariya, *J. Med. Chem.* **1990**, *33*, 317.
- [52] T. D. Heightman, P. Ermert, D. Klein, A. Vasella, *Helv. Chim. Acta* **1995**, *78*, 514.
- [53] A. R. Plant, J. E. Oliver, M. L. Patchett, R. M. Daniel, H. W. Morgan, *Arch. Biochem. Biophys.* **1988**, *262*, 181.
- [54] A. Vasella, G. J. Davies, M. Böhm, *Curr. Opin. Chem. Biol.* **2002**, *6*, 619.
- [55] R. Hoos, A. Vasella, K. Rupitz, S. G. Withers, *Carbohydr. Res.* **1997**, *298*, 291.
- [56] S. Mackay, C. J. Gilmore, C. Edwards, N. Stewart, K. Shankland, 'maXus Computer Program for the Solution and Refinement of Crystal Structures', Bruker Nonius, The Netherlands, MacScience, Japan & The University of Glasgow, 1999.
- [57] G. M. Sheldrick, 'SHELXL97. Program for the Refinement of Crystal Structures', University of Göttingen, Germany, 1997.
- [58] W. G. Kofron, L. M. Baclawski, *J. Org. Chem.* **1976**, *41*, 1879.
- [59] H. Lineweaver, D. Burk, *J. Am. Chem. Soc.* **1934**, *56*, 658.
- [60] I. H. Segel, 'Enzyme Kinetics', Wiley, New York, 1975.
- [61] Y. T. Li, *J. Biol. Chem.* **1967**, *242*, 5474.

Received July 7, 2003